TW200920350A - Use of KCNQ potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted - Google Patents

Info

Publication number

TW200920350A

TW200920350A TW097129164A TW97129164A TW200920350A TW 200920350 A TW200920350 A TW 200920350A TW 097129164 A TW097129164 A TW 097129164A TW 97129164 A TW97129164 A TW 97129164A TW 200920350 A TW200920350 A TW 200920350A

Authority

TW

Taiwan

Prior art keywords

group

phenyl

amino

alkenyl

alkyne

Prior art date

2007-08-01

Links

• Espacenet
• Global Dossier
• Discuss

• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 168
• 208000024891 symptom Diseases 0.000 title claims abstract description 94
• 230000003291 dopaminomimetic effect Effects 0.000 title claims abstract description 32
• 102000012359 KCNQ Potassium Channels Human genes 0.000 title claims abstract description 19
• 108010022282 KCNQ Potassium Channels Proteins 0.000 title claims abstract description 19
• 229940127315 Potassium Channel Openers Drugs 0.000 title 1
• 238000000034 method Methods 0.000 claims abstract description 172
• 150000001875 compounds Chemical class 0.000 claims abstract description 158
• 125000003342 alkenyl group Chemical group 0.000 claims description 809
• -1 hydroxy Chemical group 0.000 claims description 420
• 150000001336 alkenes Chemical class 0.000 claims description 369
• 150000001924 cycloalkanes Chemical class 0.000 claims description 329
• 125000002355 alkine group Chemical group 0.000 claims description 317
• 125000000304 alkynyl group Chemical group 0.000 claims description 280
• 150000001335 aliphatic alkanes Chemical class 0.000 claims description 274
• 239000002585 base Substances 0.000 claims description 242
• 150000001345 alkine derivatives Chemical class 0.000 claims description 188
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 142
• 208000035475 disorder Diseases 0.000 claims description 134
• 201000000980 schizophrenia Diseases 0.000 claims description 100
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 85
• 125000005842 heteroatom Chemical group 0.000 claims description 84
• 125000003118 aryl group Chemical group 0.000 claims description 82
• 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims description 82
• 239000000460 chlorine Substances 0.000 claims description 77
• 230000000694 effects Effects 0.000 claims description 68
• 125000001424 substituent group Chemical group 0.000 claims description 68
• 125000004432 carbon atom Chemical group C* 0.000 claims description 65
• 239000001257 hydrogen Substances 0.000 claims description 65
• 229910052739 hydrogen Inorganic materials 0.000 claims description 65
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 65
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 59
• 208000028017 Psychotic disease Diseases 0.000 claims description 55
• 229910052757 nitrogen Inorganic materials 0.000 claims description 53
• 150000002431 hydrogen Chemical class 0.000 claims description 49
• 238000011282 treatment Methods 0.000 claims description 48
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 43
• 229910052736 halogen Inorganic materials 0.000 claims description 41
• 125000000217 alkyl group Chemical group 0.000 claims description 40
• RGXWDWUGBIJHDO-UHFFFAOYSA-N decanoic acid ethyl ester Natural products CCCCCCCCCC(=O)OCC RGXWDWUGBIJHDO-UHFFFAOYSA-N 0.000 claims description 40
• 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 40
• 150000002367 halogens Chemical class 0.000 claims description 40
• 125000004429 atom Chemical group 0.000 claims description 38
• 125000004433 nitrogen atom Chemical group N* 0.000 claims description 38
• 239000007789 gas Substances 0.000 claims description 37
• 125000002009 alkene group Chemical group 0.000 claims description 36
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 36
• 239000002689 soil Substances 0.000 claims description 36
• 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 33
• 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 33
• 125000001309 chloro group Chemical group Cl* 0.000 claims description 33
• 125000005843 halogen group Chemical group 0.000 claims description 33
• 229920006395 saturated elastomer Polymers 0.000 claims description 33
• 239000000164 antipsychotic agent Substances 0.000 claims description 32
• 201000010099 disease Diseases 0.000 claims description 32
• 239000000126 substance Substances 0.000 claims description 32
• 208000011117 substance-related disease Diseases 0.000 claims description 32
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 31
• UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 30
• 201000009032 substance abuse Diseases 0.000 claims description 29
• DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 claims description 28
• 125000000623 heterocyclic group Chemical group 0.000 claims description 27
• 125000004122 cyclic group Chemical group 0.000 claims description 26
• 150000003839 salts Chemical class 0.000 claims description 26
• 208000020925 Bipolar disease Diseases 0.000 claims description 25
• 229910052786 argon Inorganic materials 0.000 claims description 25
• YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 claims description 24
• 150000001412 amines Chemical class 0.000 claims description 23
• 125000001072 heteroaryl group Chemical group 0.000 claims description 23
• 238000001228 spectrum Methods 0.000 claims description 23
• 239000000052 vinegar Substances 0.000 claims description 23
• 208000019022 Mood disease Diseases 0.000 claims description 22
• 230000000561 anti-psychotic effect Effects 0.000 claims description 22
• BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 claims description 22
• WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 21
• 206010026749 Mania Diseases 0.000 claims description 21
• 239000002253 acid Substances 0.000 claims description 21
• 125000003277 amino group Chemical group 0.000 claims description 21
• 239000003814 drug Substances 0.000 claims description 21
• OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine group Chemical group NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 21
• 235000021419 vinegar Nutrition 0.000 claims description 21
• 206010001488 Aggression Diseases 0.000 claims description 20
• 230000016571 aggressive behavior Effects 0.000 claims description 20
• 208000012761 aggressive behavior Diseases 0.000 claims description 20
• NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 20
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 19
• 206010010904 Convulsion Diseases 0.000 claims description 19
• 230000002996 emotional effect Effects 0.000 claims description 19
• 150000002500 ions Chemical class 0.000 claims description 19
• 102000005962 receptors Human genes 0.000 claims description 19
• 108020003175 receptors Proteins 0.000 claims description 19
• 229910052717 sulfur Inorganic materials 0.000 claims description 19
• 108091006146 Channels Proteins 0.000 claims description 18
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 18
• 208000018737 Parkinson disease Diseases 0.000 claims description 18
• 230000006399 behavior Effects 0.000 claims description 18
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 18
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 18
• 229940079593 drug Drugs 0.000 claims description 17
• 125000004430 oxygen atom Chemical group O* 0.000 claims description 17
• 208000012661 Dyskinesia Diseases 0.000 claims description 15
• 208000024714 major depressive disease Diseases 0.000 claims description 15
• 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims description 15
• 230000001052 transient effect Effects 0.000 claims description 15
• MHPUGCYGQWGLJL-UHFFFAOYSA-N 5-methyl-hexanoic acid Chemical compound CC(C)CCCC(O)=O MHPUGCYGQWGLJL-UHFFFAOYSA-N 0.000 claims description 14
• 208000027534 Emotional disease Diseases 0.000 claims description 14
• 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 14
• 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 14
• 125000001041 indolyl group Chemical group 0.000 claims description 14
• FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 14
• 208000020016 psychiatric disease Diseases 0.000 claims description 14
• 238000012360 testing method Methods 0.000 claims description 14
• HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 claims description 13
• 229910052799 carbon Inorganic materials 0.000 claims description 13
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 13
• 125000003396 thiol group Chemical group [H]S* 0.000 claims description 13
• 208000020401 Depressive disease Diseases 0.000 claims description 12
• 238000001354 calcination Methods 0.000 claims description 12
• 206010036790 Productive cough Diseases 0.000 claims description 11
• MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 claims description 11
• 230000033228 biological regulation Effects 0.000 claims description 11
• ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 11
• GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 claims description 11
• 125000000524 functional group Chemical group 0.000 claims description 11
• 230000001965 increasing effect Effects 0.000 claims description 11
• 150000002923 oximes Chemical class 0.000 claims description 11
• 108020001213 potassium channel Proteins 0.000 claims description 11
• 230000002829 reductive effect Effects 0.000 claims description 11
• 210000003802 sputum Anatomy 0.000 claims description 11
• 208000024794 sputum Diseases 0.000 claims description 11
• 208000011580 syndromic disease Diseases 0.000 claims description 11
• 206010012239 Delusion Diseases 0.000 claims description 10
• 102000027484 GABAA receptors Human genes 0.000 claims description 10
• 108091008681 GABAA receptors Proteins 0.000 claims description 10
• 102000004257 Potassium Channel Human genes 0.000 claims description 10
• 125000005133 alkynyloxy group Chemical group 0.000 claims description 10
• 230000036461 convulsion Effects 0.000 claims description 10
• 231100000868 delusion Toxicity 0.000 claims description 10
• 230000005764 inhibitory process Effects 0.000 claims description 10
• BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 10
• 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims description 9
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 9
• YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 9
• 208000000323 Tourette Syndrome Diseases 0.000 claims description 9
• 208000016620 Tourette disease Diseases 0.000 claims description 9
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 9
• 229940005605 valeric acid Drugs 0.000 claims description 9
• 208000024827 Alzheimer disease Diseases 0.000 claims description 8
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
• JBDSSBMEKXHSJF-UHFFFAOYSA-N cyclopentanecarboxylic acid Chemical compound OC(=O)C1CCCC1 JBDSSBMEKXHSJF-UHFFFAOYSA-N 0.000 claims description 8
• 230000006870 function Effects 0.000 claims description 8
• MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 claims description 8
• 125000001624 naphthyl group Chemical group 0.000 claims description 8
• 125000004076 pyridyl group Chemical group 0.000 claims description 8
• 230000000306 recurrent effect Effects 0.000 claims description 8
• 239000000932 sedative agent Substances 0.000 claims description 8
• 125000004434 sulfur atom Chemical group 0.000 claims description 8
• SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 7
• XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 claims description 7
• JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 claims description 7
• 201000001880 Sexual dysfunction Diseases 0.000 claims description 7
• 125000003545 alkoxy group Chemical group 0.000 claims description 7
• ZRALSGWEFCBTJO-UHFFFAOYSA-N anhydrous guanidine Natural products NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 7
• 239000000935 antidepressant agent Substances 0.000 claims description 7
• 201000007201 aphasia Diseases 0.000 claims description 7
• GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 claims description 7
• 229910052801 chlorine Inorganic materials 0.000 claims description 7
• 230000004907 flux Effects 0.000 claims description 7
• 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 claims description 7
• 230000003340 mental effect Effects 0.000 claims description 7
• 229960002715 nicotine Drugs 0.000 claims description 7
• SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 7
• 231100000872 sexual dysfunction Toxicity 0.000 claims description 7
• GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims description 6
• GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims description 6
• 206010012289 Dementia Diseases 0.000 claims description 6
• GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims description 6
• KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 claims description 6
• 230000001800 adrenalinergic effect Effects 0.000 claims description 6
• 230000003561 anti-manic effect Effects 0.000 claims description 6
• 229940005513 antidepressants Drugs 0.000 claims description 6
• 229940005529 antipsychotics Drugs 0.000 claims description 6
• 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 6
• 230000001149 cognitive effect Effects 0.000 claims description 6
• 229960002069 diamorphine Drugs 0.000 claims description 6
• 230000033001 locomotion Effects 0.000 claims description 6
• 230000007774 longterm Effects 0.000 claims description 6
• 229960005181 morphine Drugs 0.000 claims description 6
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
• 229910052760 oxygen Inorganic materials 0.000 claims description 6
• 239000003368 psychostimulant agent Substances 0.000 claims description 6
• 229910052707 ruthenium Inorganic materials 0.000 claims description 6
• 229940125723 sedative agent Drugs 0.000 claims description 6
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 6
• 229930192474 thiophene Natural products 0.000 claims description 6
• 125000003944 tolyl group Chemical group 0.000 claims description 6
• OXRCIXHTUHZNRY-UHFFFAOYSA-N 2-cyclopentylacetamide Chemical compound NC(=O)CC1CCCC1 OXRCIXHTUHZNRY-UHFFFAOYSA-N 0.000 claims description 5
• RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 5
• 241000218236 Cannabis Species 0.000 claims description 5
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 5
• 241001465754 Metazoa Species 0.000 claims description 5
• OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 claims description 5
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
• 125000006269 biphenyl-2-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C(*)C([H])=C([H])C([H])=C1[H] 0.000 claims description 5
• 150000002148 esters Chemical class 0.000 claims description 5
• WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 claims description 5
• 230000000670 limiting effect Effects 0.000 claims description 5
• 230000010534 mechanism of action Effects 0.000 claims description 5
• 239000000203 mixture Substances 0.000 claims description 5
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 5
• 230000001105 regulatory effect Effects 0.000 claims description 5
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
• BGRWYRAHAFMIBJ-UHFFFAOYSA-N 1,3-di(propan-2-yl)urea Chemical compound CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 claims description 4
• PAJPWUMXBYXFCZ-UHFFFAOYSA-N 1-aminocyclopropanecarboxylic acid Chemical compound OC(=O)C1(N)CC1 PAJPWUMXBYXFCZ-UHFFFAOYSA-N 0.000 claims description 4
• IHWDSEPNZDYMNF-UHFFFAOYSA-N 1H-indol-2-amine Chemical compound C1=CC=C2NC(N)=CC2=C1 IHWDSEPNZDYMNF-UHFFFAOYSA-N 0.000 claims description 4
• 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 4
• CNPURSDMOWDNOQ-UHFFFAOYSA-N 4-methoxy-7h-pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound COC1=NC(N)=NC2=C1C=CN2 CNPURSDMOWDNOQ-UHFFFAOYSA-N 0.000 claims description 4
• CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims description 4
• 125000005577 anthracene group Chemical group 0.000 claims description 4
• 125000005605 benzo group Chemical group 0.000 claims description 4
• 229960003920 cocaine Drugs 0.000 claims description 4
• TXWOGHSRPAYOML-UHFFFAOYSA-N cyclobutanecarboxylic acid Chemical compound OC(=O)C1CCC1 TXWOGHSRPAYOML-UHFFFAOYSA-N 0.000 claims description 4
• SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims description 4
• 238000010494 dissociation reaction Methods 0.000 claims description 4
• 230000005593 dissociations Effects 0.000 claims description 4
• 125000004494 ethyl ester group Chemical group 0.000 claims description 4
• FGKJLKRYENPLQH-UHFFFAOYSA-N isocaproic acid Chemical compound CC(C)CCC(O)=O FGKJLKRYENPLQH-UHFFFAOYSA-N 0.000 claims description 4
• 239000008267 milk Substances 0.000 claims description 4
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
• 239000001301 oxygen Substances 0.000 claims description 4
• 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 4
• 229910052700 potassium Inorganic materials 0.000 claims description 4
• 208000019116 sleep disease Diseases 0.000 claims description 4
• 239000013589 supplement Substances 0.000 claims description 4
• 230000001755 vocal effect Effects 0.000 claims description 4
• 230000004580 weight loss Effects 0.000 claims description 4
• AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 claims description 3
• XIMFTYYMYOBGOG-UHFFFAOYSA-N 2-hydroxy-2-(2-oxo-2-propoxyethyl)butanedioic acid Chemical compound CCCOC(=O)CC(O)(C(O)=O)CC(O)=O XIMFTYYMYOBGOG-UHFFFAOYSA-N 0.000 claims description 3
• GPWHFPWZAPOYNO-UHFFFAOYSA-N 3,3-dimethylbutan-1-amine Chemical compound CC(C)(C)CCN GPWHFPWZAPOYNO-UHFFFAOYSA-N 0.000 claims description 3
• 206010002942 Apathy Diseases 0.000 claims description 3
• YPUWSOVUQFIXDH-UHFFFAOYSA-N C(CCCCCCCCC)(=O)O.C1CCCCC1 Chemical compound C(CCCCCCCCC)(=O)O.C1CCCCC1 YPUWSOVUQFIXDH-UHFFFAOYSA-N 0.000 claims description 3
• 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 claims description 3
• 206010014557 Emotional poverty Diseases 0.000 claims description 3
• 240000006890 Erythroxylum coca Species 0.000 claims description 3
• 208000023105 Huntington disease Diseases 0.000 claims description 3
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 3
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 3
• 206010056326 Transient psychosis Diseases 0.000 claims description 3
• 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 3
• IGIDLTISMCAULB-UHFFFAOYSA-N anteisohexanoic acid Natural products CCC(C)CC(O)=O IGIDLTISMCAULB-UHFFFAOYSA-N 0.000 claims description 3
• 230000001430 anti-depressive effect Effects 0.000 claims description 3
• 230000015572 biosynthetic process Effects 0.000 claims description 3
• KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims description 3
• 235000008957 cocaer Nutrition 0.000 claims description 3
• 238000004891 communication Methods 0.000 claims description 3
• 230000034994 death Effects 0.000 claims description 3
• 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
• 230000006735 deficit Effects 0.000 claims description 3
• 230000008482 dysregulation Effects 0.000 claims description 3
• 230000008451 emotion Effects 0.000 claims description 3
• 239000012458 free base Substances 0.000 claims description 3
• 125000005343 heterocyclic alkyl group Chemical group 0.000 claims description 3
• 230000008449 language Effects 0.000 claims description 3
• QUSNBJAOOMFDIB-UHFFFAOYSA-N monoethyl amine Natural products CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims description 3
• JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 claims description 3
• 229940005483 opioid analgesics Drugs 0.000 claims description 3
• 230000035807 sensation Effects 0.000 claims description 3
• 238000006467 substitution reaction Methods 0.000 claims description 3
• 239000011593 sulfur Substances 0.000 claims description 3
• 238000012546 transfer Methods 0.000 claims description 3
• RFFLAFLAYFXFSW-UHFFFAOYSA-N 1,2-dichlorobenzene Chemical compound ClC1=CC=CC=C1Cl RFFLAFLAYFXFSW-UHFFFAOYSA-N 0.000 claims description 2
• VZXTWGWHSMCWGA-UHFFFAOYSA-N 1,3,5-triazine-2,4-diamine Chemical compound NC1=NC=NC(N)=N1 VZXTWGWHSMCWGA-UHFFFAOYSA-N 0.000 claims description 2
• ZAYJLLOZEKWCBU-UHFFFAOYSA-N 1-[1-[(5-chlorothiophen-2-yl)methyl]-2,3-dihydroindol-5-yl]-3-ethylurea Chemical compound C1CC2=CC(NC(=O)NCC)=CC=C2N1CC1=CC=C(Cl)S1 ZAYJLLOZEKWCBU-UHFFFAOYSA-N 0.000 claims description 2
• LLIJZRLDYOMJMP-UHFFFAOYSA-N 1-benzyl-3-[1-[(5-chlorothiophen-2-yl)methyl]-2,3-dihydroindol-5-yl]urea Chemical compound S1C(Cl)=CC=C1CN1C2=CC=C(NC(=O)NCC=3C=CC=CC=3)C=C2CC1 LLIJZRLDYOMJMP-UHFFFAOYSA-N 0.000 claims description 2
• 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims description 2
• 125000006304 2-iodophenyl group Chemical group [H]C1=C([H])C(I)=C(*)C([H])=C1[H] 0.000 claims description 2
• 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
• OILUAKBAMVLXGF-UHFFFAOYSA-N 3,5,5-trimethyl-hexanoic acid Chemical compound OC(=O)CC(C)CC(C)(C)C OILUAKBAMVLXGF-UHFFFAOYSA-N 0.000 claims description 2
• HRIDWDUZRHVEGN-UHFFFAOYSA-N 3-ethyldecanoic acid Chemical compound CCCCCCCC(CC)CC(O)=O HRIDWDUZRHVEGN-UHFFFAOYSA-N 0.000 claims description 2
• NEAFWRKPYYJETG-UHFFFAOYSA-N 4-sulfanylpentanoic acid Chemical compound CC(S)CCC(O)=O NEAFWRKPYYJETG-UHFFFAOYSA-N 0.000 claims description 2
• ODGIMMLDVSWADK-UHFFFAOYSA-N 4-trifluoromethylaniline Chemical compound NC1=CC=C(C(F)(F)F)C=C1 ODGIMMLDVSWADK-UHFFFAOYSA-N 0.000 claims description 2
• 125000001318 4-trifluoromethylbenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])*)C(F)(F)F 0.000 claims description 2
• WRSIVVCVPYCMFP-UHFFFAOYSA-N CCCCNC1=CC2=C(C=C1)N(CC2)CC3=CC=C(S3)Cl Chemical compound CCCCNC1=CC2=C(C=C1)N(CC2)CC3=CC=C(S3)Cl WRSIVVCVPYCMFP-UHFFFAOYSA-N 0.000 claims description 2
• ZUHMQYWQWQDAET-UHFFFAOYSA-N CCCCNC1=CC=C(C=C1)CNC2=CC(=C(C=C2)Cl)Cl Chemical compound CCCCNC1=CC=C(C=C1)CNC2=CC(=C(C=C2)Cl)Cl ZUHMQYWQWQDAET-UHFFFAOYSA-N 0.000 claims description 2
• 206010010144 Completed suicide Diseases 0.000 claims description 2
• XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 claims description 2
• 206010017711 Gangrene Diseases 0.000 claims description 2
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
• 150000001408 amides Chemical class 0.000 claims description 2
• 239000012298 atmosphere Substances 0.000 claims description 2
• 208000028683 bipolar I disease Diseases 0.000 claims description 2
• 230000000903 blocking effect Effects 0.000 claims description 2
• 239000000470 constituent Substances 0.000 claims description 2
• 230000003001 depressive effect Effects 0.000 claims description 2
• OCOIXRNXFUKTKY-UHFFFAOYSA-N ethyl n-[2-amino-4-[(5-ethylthiophen-2-yl)methylamino]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(CC)S1 OCOIXRNXFUKTKY-UHFFFAOYSA-N 0.000 claims description 2
• QEYNFGCIULPLPC-UHFFFAOYSA-N ethyl n-[4-[(3-fluoroanilino)methyl]-2,6-dimethylphenyl]carbamate Chemical compound C1=C(C)C(NC(=O)OCC)=C(C)C=C1CNC1=CC=CC(F)=C1 QEYNFGCIULPLPC-UHFFFAOYSA-N 0.000 claims description 2
• 150000002391 heterocyclic compounds Chemical class 0.000 claims description 2
• 239000012535 impurity Substances 0.000 claims description 2
• 239000008101 lactose Substances 0.000 claims description 2
• 230000015654 memory Effects 0.000 claims description 2
• 230000036651 mood Effects 0.000 claims description 2
• QOQVAAXPPGQOFT-UHFFFAOYSA-N n-[1-[(5-chlorothiophen-2-yl)methyl]-6-nitro-2,3-dihydroindol-5-yl]-2,2-dimethylpropanamide Chemical compound C1=2C=C([N+]([O-])=O)C(NC(=O)C(C)(C)C)=CC=2CCN1CC1=CC=C(Cl)S1 QOQVAAXPPGQOFT-UHFFFAOYSA-N 0.000 claims description 2
• TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 claims description 2
• 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 claims description 2
• 238000002360 preparation method Methods 0.000 claims description 2
• BXPLVYLJBOHLAC-UHFFFAOYSA-N propyl n-[2-iodo-4-[(4-propan-2-ylphenyl)methylamino]phenyl]carbamate Chemical compound C1=C(I)C(NC(=O)OCCC)=CC=C1NCC1=CC=C(C(C)C)C=C1 BXPLVYLJBOHLAC-UHFFFAOYSA-N 0.000 claims description 2
• QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims description 2
• NYCVCXMSZNOGDH-UHFFFAOYSA-N pyrrolidine-1-carboxylic acid Chemical compound OC(=O)N1CCCC1 NYCVCXMSZNOGDH-UHFFFAOYSA-N 0.000 claims description 2
• 230000001568 sexual effect Effects 0.000 claims description 2
• 241000894007 species Species 0.000 claims description 2
• DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 4
• 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 3
• MHZGKXUYDGKKIU-UHFFFAOYSA-N Decylamine Chemical compound CCCCCCCCCCN MHZGKXUYDGKKIU-UHFFFAOYSA-N 0.000 claims 3
• METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 claims 3
• BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Substances OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims 3
• 125000003107 substituted aryl group Chemical group 0.000 claims 3
• LCGPJLNETXSCJW-UHFFFAOYSA-N 2-amino-4-sulfanylpentanoic acid Chemical compound CC(S)CC(N)C(O)=O LCGPJLNETXSCJW-UHFFFAOYSA-N 0.000 claims 2
• TUCRZHGAIRVWTI-UHFFFAOYSA-N 2-bromothiophene Chemical compound BrC1=CC=CS1 TUCRZHGAIRVWTI-UHFFFAOYSA-N 0.000 claims 2
• CVKMFSAVYPAZTQ-UHFFFAOYSA-N 2-methylhexanoic acid Chemical compound CCCCC(C)C(O)=O CVKMFSAVYPAZTQ-UHFFFAOYSA-N 0.000 claims 2
• 125000003352 4-tert-butyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])*)C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
• OQLZINXFSUDMHM-UHFFFAOYSA-N Acetamidine Chemical compound CC(N)=N OQLZINXFSUDMHM-UHFFFAOYSA-N 0.000 claims 2
• QCOGKXLOEWLIDC-UHFFFAOYSA-N N-methylbutylamine Chemical compound CCCCNC QCOGKXLOEWLIDC-UHFFFAOYSA-N 0.000 claims 2
• 229910052785 arsenic Inorganic materials 0.000 claims 2
• RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 claims 2
• HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 claims 2
• MGWAVDBGNNKXQV-UHFFFAOYSA-N diisobutyl phthalate Chemical compound CC(C)COC(=O)C1=CC=CC=C1C(=O)OCC(C)C MGWAVDBGNNKXQV-UHFFFAOYSA-N 0.000 claims 2
• 239000010200 folin Substances 0.000 claims 2
• YNTOKMNHRPSGFU-UHFFFAOYSA-N n-Propyl carbamate Chemical compound CCCOC(N)=O YNTOKMNHRPSGFU-UHFFFAOYSA-N 0.000 claims 2
• WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 claims 2
• UKPBXIFLSVLDPA-UHFFFAOYSA-N propylhydrazine Chemical compound CCCNN UKPBXIFLSVLDPA-UHFFFAOYSA-N 0.000 claims 2
• PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims 2
• IGIDLTISMCAULB-YFKPBYRVSA-N (3s)-3-methylpentanoic acid Chemical compound CC[C@H](C)CC(O)=O IGIDLTISMCAULB-YFKPBYRVSA-N 0.000 claims 1
• POJYSQCMDUIYSB-UHFFFAOYSA-N (anilinoazaniumyl)formate Chemical compound OC(=O)NNC1=CC=CC=C1 POJYSQCMDUIYSB-UHFFFAOYSA-N 0.000 claims 1
• MFLYTCSVJYYAOR-UHFFFAOYSA-N (carbamimidoylazaniumyl)formate Chemical compound NC(=N)NC(O)=O MFLYTCSVJYYAOR-UHFFFAOYSA-N 0.000 claims 1
• JBARPWSDHRKCOV-UHFFFAOYSA-N 1-[1-[(5-chlorothiophen-2-yl)methyl]-2,3-dihydroindol-5-yl]-3-(2-phenylethyl)urea Chemical compound S1C(Cl)=CC=C1CN1C2=CC=C(NC(=O)NCCC=3C=CC=CC=3)C=C2CC1 JBARPWSDHRKCOV-UHFFFAOYSA-N 0.000 claims 1
• KWTSXDURSIMDCE-UHFFFAOYSA-N 1-phenylpropan-2-amine Chemical compound CC(N)CC1=CC=CC=C1 KWTSXDURSIMDCE-UHFFFAOYSA-N 0.000 claims 1
• NRKYWOKHZRQRJR-UHFFFAOYSA-N 2,2,2-trifluoroacetamide Chemical compound NC(=O)C(F)(F)F NRKYWOKHZRQRJR-UHFFFAOYSA-N 0.000 claims 1
• KIPSRYDSZQRPEA-UHFFFAOYSA-N 2,2,2-trifluoroethanamine Chemical compound NCC(F)(F)F KIPSRYDSZQRPEA-UHFFFAOYSA-N 0.000 claims 1
• LBMVNBZGHAZJNN-UHFFFAOYSA-N 2-(4-fluorophenyl)ethanimidamide Chemical compound NC(=N)CC1=CC=C(F)C=C1 LBMVNBZGHAZJNN-UHFFFAOYSA-N 0.000 claims 1
• OLKQIWCQICCYQS-UHFFFAOYSA-N 2-(4-methoxyphenyl)acetamide Chemical compound COC1=CC=C(CC(N)=O)C=C1 OLKQIWCQICCYQS-UHFFFAOYSA-N 0.000 claims 1
• WHPLBPSDTIZFSX-UHFFFAOYSA-N 2-(4-phenylphenyl)ethanamine Chemical compound C1=CC(CCN)=CC=C1C1=CC=CC=C1 WHPLBPSDTIZFSX-UHFFFAOYSA-N 0.000 claims 1
• AVMSWPWPYJVYKY-UHFFFAOYSA-N 2-Methylpropyl formate Chemical compound CC(C)COC=O AVMSWPWPYJVYKY-UHFFFAOYSA-N 0.000 claims 1
• ULKJRSJOIDFZPK-UHFFFAOYSA-N 2-cyclopentyl-n-(2,4-dimethyl-6-phenylphenyl)acetamide Chemical compound C=1C=CC=CC=1C1=CC(C)=CC(C)=C1NC(=O)CC1CCCC1 ULKJRSJOIDFZPK-UHFFFAOYSA-N 0.000 claims 1
• NDPLBCRXHOVZML-UHFFFAOYSA-N 2-cyclopentyl-n-[2,6-dichloro-4-[(4-fluoroanilino)methyl]phenyl]acetamide Chemical compound C1=CC(F)=CC=C1NCC(C=C1Cl)=CC(Cl)=C1NC(=O)CC1CCCC1 NDPLBCRXHOVZML-UHFFFAOYSA-N 0.000 claims 1
• BHVKYMSGYOOSCM-UHFFFAOYSA-N 2-cyclopentyl-n-[2,6-dimethyl-4-[[3-(trifluoromethyl)anilino]methyl]phenyl]acetamide Chemical compound C=1C(C)=C(NC(=O)CC2CCCC2)C(C)=CC=1CNC1=CC=CC(C(F)(F)F)=C1 BHVKYMSGYOOSCM-UHFFFAOYSA-N 0.000 claims 1
• MTEZLAATISORQK-UHFFFAOYSA-N 2-methoxyacetamide Chemical compound COCC(N)=O MTEZLAATISORQK-UHFFFAOYSA-N 0.000 claims 1
• AHDDRJBFJBDEPW-UHFFFAOYSA-N 2-phenylcyclopropane-1-carboxylic acid Chemical compound OC(=O)C1CC1C1=CC=CC=C1 AHDDRJBFJBDEPW-UHFFFAOYSA-N 0.000 claims 1
• UUPZTFTUZUQRQT-UHFFFAOYSA-N 2-thiophen-2-ylacetamide Chemical compound NC(=O)CC1=CC=CS1 UUPZTFTUZUQRQT-UHFFFAOYSA-N 0.000 claims 1
• 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims 1
• HNNQYHFROJDYHQ-UHFFFAOYSA-N 3-(4-ethylcyclohexyl)propanoic acid 3-(3-ethylcyclopentyl)propanoic acid Chemical compound CCC1CCC(CCC(O)=O)C1.CCC1CCC(CCC(O)=O)CC1 HNNQYHFROJDYHQ-UHFFFAOYSA-N 0.000 claims 1
• 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 1
• BXCCPISTXNCJQT-UHFFFAOYSA-N 3-methoxybut-1-ynylbenzene Chemical compound COC(C#CC1=CC=CC=C1)C BXCCPISTXNCJQT-UHFFFAOYSA-N 0.000 claims 1
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims 1
• OGIQUQKNJJTLSZ-UHFFFAOYSA-N 4-butylaniline Chemical compound CCCCC1=CC=C(N)C=C1 OGIQUQKNJJTLSZ-UHFFFAOYSA-N 0.000 claims 1
• QSNSCYSYFYORTR-UHFFFAOYSA-N 4-chloroaniline Chemical compound NC1=CC=C(Cl)C=C1 QSNSCYSYFYORTR-UHFFFAOYSA-N 0.000 claims 1
• IOYLGISQRDBPQT-UHFFFAOYSA-N 4-n-[(4-fluorophenyl)methyl]benzene-1,2,4-triamine Chemical compound C1=C(N)C(N)=CC=C1NCC1=CC=C(F)C=C1 IOYLGISQRDBPQT-UHFFFAOYSA-N 0.000 claims 1
• BDUUYZWYAVGTOK-UHFFFAOYSA-N 5-methyl-decanoic acid Chemical compound CCCCCC(C)CCCC(O)=O BDUUYZWYAVGTOK-UHFFFAOYSA-N 0.000 claims 1
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical group N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 1
• 241000239290 Araneae Species 0.000 claims 1
• GXZOTMVPGOWSMK-UHFFFAOYSA-N CCCCCCCCC(C(OCC)=O)NC1=CC=CC=C1 Chemical compound CCCCCCCCC(C(OCC)=O)NC1=CC=CC=C1 GXZOTMVPGOWSMK-UHFFFAOYSA-N 0.000 claims 1
• STTTZAKWIFHRKG-UHFFFAOYSA-N CCCCNC1=C(C=C(C=C1)CNC2=CC(=CC=C2)F)F Chemical compound CCCCNC1=C(C=C(C=C1)CNC2=CC(=CC=C2)F)F STTTZAKWIFHRKG-UHFFFAOYSA-N 0.000 claims 1
• 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 claims 1
• 240000006432 Carica papaya Species 0.000 claims 1
• 235000009467 Carica papaya Nutrition 0.000 claims 1
• 102000015554 Dopamine receptor Human genes 0.000 claims 1
• 108050004812 Dopamine receptor Proteins 0.000 claims 1
• 101700012268 Holin Proteins 0.000 claims 1
• SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 1
• RMOUBSOVHSONPZ-UHFFFAOYSA-N Isopropyl formate Chemical compound CC(C)OC=O RMOUBSOVHSONPZ-UHFFFAOYSA-N 0.000 claims 1
• DJEQZVQFEPKLOY-UHFFFAOYSA-N N,N-dimethylbutylamine Chemical compound CCCCN(C)C DJEQZVQFEPKLOY-UHFFFAOYSA-N 0.000 claims 1
• 241000282376 Panthera tigris Species 0.000 claims 1
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 1
• XJZHWYPJRSSMJW-UHFFFAOYSA-N [4-[(5-bromothiophen-2-yl)methylamino]-2-(trifluoromethyl)phenyl]carbamic acid Chemical compound C1=C(C(F)(F)F)C(NC(=O)O)=CC=C1NCC1=CC=C(Br)S1 XJZHWYPJRSSMJW-UHFFFAOYSA-N 0.000 claims 1
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
• 125000004423 acyloxy group Chemical group 0.000 claims 1
• 239000003513 alkali Substances 0.000 claims 1
• PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 claims 1
• 150000004056 anthraquinones Chemical class 0.000 claims 1
• DMVOXQPQNTYEKQ-UHFFFAOYSA-N biphenyl-4-amine Chemical compound C1=CC(N)=CC=C1C1=CC=CC=C1 DMVOXQPQNTYEKQ-UHFFFAOYSA-N 0.000 claims 1
• 239000001273 butane Substances 0.000 claims 1
• 239000004202 carbamide Substances 0.000 claims 1
• 125000004802 cyanophenyl group Chemical group 0.000 claims 1
• 150000001925 cycloalkenes Chemical class 0.000 claims 1
• 125000002993 cycloalkylene group Chemical group 0.000 claims 1
• 230000007547 defect Effects 0.000 claims 1
• 210000004268 dentin Anatomy 0.000 claims 1
• 230000001419 dependent effect Effects 0.000 claims 1
• QGBSISYHAICWAH-UHFFFAOYSA-N dicyandiamide Chemical compound NC(N)=NC#N QGBSISYHAICWAH-UHFFFAOYSA-N 0.000 claims 1
• 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims 1
• DMBHHRLKUKUOEG-UHFFFAOYSA-N diphenylamine Chemical compound C=1C=CC=CC=1NC1=CC=CC=C1 DMBHHRLKUKUOEG-UHFFFAOYSA-N 0.000 claims 1
• GABQKHQNXWNJJJ-UHFFFAOYSA-N diphenylcarbamic acid Chemical compound C=1C=CC=CC=1N(C(=O)O)C1=CC=CC=C1 GABQKHQNXWNJJJ-UHFFFAOYSA-N 0.000 claims 1
• CZZYITDELCSZES-UHFFFAOYSA-N diphenylmethane Chemical group C=1C=CC=CC=1CC1=CC=CC=C1 CZZYITDELCSZES-UHFFFAOYSA-N 0.000 claims 1
• 201000006549 dyspepsia Diseases 0.000 claims 1
• BSCJHOFVPMMXGC-UHFFFAOYSA-N ethyl n-[2-amino-4-[(4-methoxyanilino)methyl]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1CNC1=CC=C(OC)C=C1 BSCJHOFVPMMXGC-UHFFFAOYSA-N 0.000 claims 1
• CIYWTQMAZIEXNG-UHFFFAOYSA-N ethyl n-[2-amino-4-[(4-methylanilino)methyl]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1CNC1=CC=C(C)C=C1 CIYWTQMAZIEXNG-UHFFFAOYSA-N 0.000 claims 1
• HIDMNWJFCJAMQI-UHFFFAOYSA-N ethyl n-[2-chloro-4-[(3-fluoroanilino)methyl]phenyl]carbamate Chemical compound C1=C(Cl)C(NC(=O)OCC)=CC=C1CNC1=CC=CC(F)=C1 HIDMNWJFCJAMQI-UHFFFAOYSA-N 0.000 claims 1
• QCEHDLKQWVGPFI-UHFFFAOYSA-N ethyl n-[4-[(4-chlorophenyl)methylamino]-2-methylphenyl]carbamate Chemical compound C1=C(C)C(NC(=O)OCC)=CC=C1NCC1=CC=C(Cl)C=C1 QCEHDLKQWVGPFI-UHFFFAOYSA-N 0.000 claims 1
• 235000019253 formic acid Nutrition 0.000 claims 1
• 230000002496 gastric effect Effects 0.000 claims 1
• 229910052732 germanium Inorganic materials 0.000 claims 1
• GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical group [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 claims 1
• 210000004907 gland Anatomy 0.000 claims 1
• BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical compound NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 claims 1
• 208000024798 heartburn Diseases 0.000 claims 1
• 229910052734 helium Inorganic materials 0.000 claims 1
• SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical group [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 claims 1
• AEDIXYWIVPYNBI-UHFFFAOYSA-N heptanamide Chemical compound CCCCCCC(N)=O AEDIXYWIVPYNBI-UHFFFAOYSA-N 0.000 claims 1
• 239000010977 jade Substances 0.000 claims 1
• 229910052746 lanthanum Inorganic materials 0.000 claims 1
• FZLIPJUXYLNCLC-UHFFFAOYSA-N lanthanum atom Chemical compound [La] FZLIPJUXYLNCLC-UHFFFAOYSA-N 0.000 claims 1
• 230000006996 mental state Effects 0.000 claims 1
• UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 claims 1
• 229940105132 myristate Drugs 0.000 claims 1
• COFKFSSWMQHKMD-UHFFFAOYSA-N n,n-didecyldecan-1-amine Chemical compound CCCCCCCCCCN(CCCCCCCCCC)CCCCCCCCCC COFKFSSWMQHKMD-UHFFFAOYSA-N 0.000 claims 1
• UANXUOHOUIPKAT-UHFFFAOYSA-N n-(2,4-dimethyl-6-quinolin-3-ylphenyl)-2-(4-fluorophenyl)acetamide Chemical compound C=1N=C2C=CC=CC2=CC=1C1=CC(C)=CC(C)=C1NC(=O)CC1=CC=C(F)C=C1 UANXUOHOUIPKAT-UHFFFAOYSA-N 0.000 claims 1
• GLBDFDMKCASXQQ-UHFFFAOYSA-N n-(4-bromo-2,6-dimethylphenyl)-2-cyclopentylacetamide Chemical compound CC1=CC(Br)=CC(C)=C1NC(=O)CC1CCCC1 GLBDFDMKCASXQQ-UHFFFAOYSA-N 0.000 claims 1
• JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims 1
• ISMXZIBRJLAXBF-UHFFFAOYSA-N n-[2-[4-(dimethylamino)phenyl]-4,6-dimethylphenyl]-2-(4-fluorophenyl)acetamide Chemical compound C1=CC(N(C)C)=CC=C1C1=CC(C)=CC(C)=C1NC(=O)CC1=CC=C(F)C=C1 ISMXZIBRJLAXBF-UHFFFAOYSA-N 0.000 claims 1
• XEQYECZAIUQLSF-UHFFFAOYSA-N n-[2-chloro-4-[(5-chlorothiophen-2-yl)methyl-methylamino]phenyl]-3-phenylpropanamide Chemical compound C=1C=C(NC(=O)CCC=2C=CC=CC=2)C(Cl)=CC=1N(C)CC1=CC=C(Cl)S1 XEQYECZAIUQLSF-UHFFFAOYSA-N 0.000 claims 1
• NDZPOHAYEUWMTA-UHFFFAOYSA-N n-[2-methyl-4-[[4-(trifluoromethyl)phenyl]methylamino]phenyl]-2-piperidin-1-ylacetamide Chemical compound C=1C=C(NC(=O)CN2CCCCC2)C(C)=CC=1NCC1=CC=C(C(F)(F)F)C=C1 NDZPOHAYEUWMTA-UHFFFAOYSA-N 0.000 claims 1
• OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims 1
• UFWIBTONFRDIAS-UHFFFAOYSA-N naphthalene-acid Natural products C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims 1
• 235000015097 nutrients Nutrition 0.000 claims 1
• XNGIFLGASWRNHJ-UHFFFAOYSA-N o-dicarboxybenzene Natural products OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 claims 1
• 238000012261 overproduction Methods 0.000 claims 1
• 229960005489 paracetamol Drugs 0.000 claims 1
• 230000002085 persistent effect Effects 0.000 claims 1
• SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical group CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 claims 1
• SNWAFDKDRJRUCS-UHFFFAOYSA-N propyl n-[2-(trifluoromethyl)-4-[[4-(trifluoromethyl)phenyl]methylamino]phenyl]carbamate Chemical compound C1=C(C(F)(F)F)C(NC(=O)OCCC)=CC=C1NCC1=CC=C(C(F)(F)F)C=C1 SNWAFDKDRJRUCS-UHFFFAOYSA-N 0.000 claims 1
• QHMVGVWNQLCEIC-UHFFFAOYSA-N propyl n-[2-bromo-4-[(4-methylsulfanylphenyl)methylamino]phenyl]carbamate Chemical compound C1=C(Br)C(NC(=O)OCCC)=CC=C1NCC1=CC=C(SC)C=C1 QHMVGVWNQLCEIC-UHFFFAOYSA-N 0.000 claims 1
• VACFMSSWACPZHI-UHFFFAOYSA-N propyl n-[2-methyl-4-[(4-propan-2-ylphenyl)methylamino]phenyl]carbamate Chemical compound C1=C(C)C(NC(=O)OCCC)=CC=C1NCC1=CC=C(C(C)C)C=C1 VACFMSSWACPZHI-UHFFFAOYSA-N 0.000 claims 1
• 230000006207 propylation Effects 0.000 claims 1
• 230000010349 pulsation Effects 0.000 claims 1
• 150000004053 quinones Chemical class 0.000 claims 1
• 201000000424 schizophrenia 13 Diseases 0.000 claims 1
• 201000000372 schizophrenia 4 Diseases 0.000 claims 1
• 235000015096 spirit Nutrition 0.000 claims 1
• 229940032094 squalane Drugs 0.000 claims 1
• PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical group C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 claims 1
• 239000000758 substrate Substances 0.000 claims 1
• 229910021653 sulphate ion Inorganic materials 0.000 claims 1
• 239000000725 suspension Substances 0.000 claims 1
• 125000005301 thienylmethyl group Chemical group [H]C1=C([H])C([H])=C(S1)C([H])([H])* 0.000 claims 1
• ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 claims 1
• RSPCKAHMRANGJZ-UHFFFAOYSA-N thiohydroxylamine Chemical compound SN RSPCKAHMRANGJZ-UHFFFAOYSA-N 0.000 claims 1
• KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 claims 1
• 125000006493 trifluoromethyl benzyl group Chemical group 0.000 claims 1
• GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 claims 1
• 230000014509 gene expression Effects 0.000 description 22
• NIHNNTQXNPWCJQ-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 19
• 125000002950 monocyclic group Chemical group 0.000 description 19
• 125000000392 cycloalkenyl group Chemical group 0.000 description 16
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 14
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 13
• KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 13
• 125000002619 bicyclic group Chemical group 0.000 description 13
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 12
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 12
• PCOBBVZJEWWZFR-UHFFFAOYSA-N ezogabine Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 PCOBBVZJEWWZFR-UHFFFAOYSA-N 0.000 description 12
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 12
• 229960003312 retigabine Drugs 0.000 description 12
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 11
• HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 11
• 230000008092 positive effect Effects 0.000 description 11
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 11
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 10
• VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 10
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
• 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 9
• 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 9
• KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 8
• 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 8
• 150000001721 carbon Chemical group 0.000 description 8
• 208000013403 hyperactivity Diseases 0.000 description 8
• 102000004980 Dopamine D2 Receptors Human genes 0.000 description 7
• 108090001111 Dopamine D2 Receptors Proteins 0.000 description 7
• 101000994648 Homo sapiens Potassium voltage-gated channel subfamily KQT member 4 Proteins 0.000 description 7
• 229940025084 amphetamine Drugs 0.000 description 7
• 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 7
• 210000004027 cell Anatomy 0.000 description 7
• 238000001727 in vivo Methods 0.000 description 7
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 7
• 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 7
• YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
• 239000001961 anticonvulsive agent Substances 0.000 description 6
• 125000001246 bromo group Chemical group Br* 0.000 description 6
• 239000003795 chemical substances by application Substances 0.000 description 6
• 230000001684 chronic effect Effects 0.000 description 6
• 125000001153 fluoro group Chemical group F* 0.000 description 6
• 210000004209 hair Anatomy 0.000 description 6
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 6
• 230000001225 therapeutic effect Effects 0.000 description 6
• 108010006746 KCNQ2 Potassium Channel Proteins 0.000 description 5
• 230000008485 antagonism Effects 0.000 description 5
• 210000004556 brain Anatomy 0.000 description 5
• 229960003638 dopamine Drugs 0.000 description 5
• 230000002452 interceptive effect Effects 0.000 description 5
• 238000012216 screening Methods 0.000 description 5
• 210000004515 ventral tegmental area Anatomy 0.000 description 5
• 229920002554 vinyl polymer Polymers 0.000 description 5
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 4
• 208000004547 Hallucinations Diseases 0.000 description 4
• 108010038888 KCNQ3 Potassium Channel Proteins 0.000 description 4
• 208000019430 Motor disease Diseases 0.000 description 4
• 102100034354 Potassium voltage-gated channel subfamily KQT member 2 Human genes 0.000 description 4
• 230000001154 acute effect Effects 0.000 description 4
• 125000002947 alkylene group Chemical group 0.000 description 4
• 230000001773 anti-convulsant effect Effects 0.000 description 4
• 229960003965 antiepileptics Drugs 0.000 description 4
• HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 4
• 230000008901 benefit Effects 0.000 description 4
• 125000002837 carbocyclic group Chemical group 0.000 description 4
• 206010015037 epilepsy Diseases 0.000 description 4
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 4
• 238000011866 long-term treatment Methods 0.000 description 4
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
• 238000011458 pharmacological treatment Methods 0.000 description 4
• 230000002265 prevention Effects 0.000 description 4
• 108090000623 proteins and genes Proteins 0.000 description 4
• 150000003230 pyrimidines Chemical class 0.000 description 4
• 150000003254 radicals Chemical class 0.000 description 4
• 230000004044 response Effects 0.000 description 4
• 238000002560 therapeutic procedure Methods 0.000 description 4
• BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 description 3
• 101150049660 DRD2 gene Proteins 0.000 description 3
• 208000016285 Movement disease Diseases 0.000 description 3
• 208000009668 Neurobehavioral Manifestations Diseases 0.000 description 3
• WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 3
• 208000002193 Pain Diseases 0.000 description 3
• 102100034360 Potassium voltage-gated channel subfamily KQT member 3 Human genes 0.000 description 3
• 102100034363 Potassium voltage-gated channel subfamily KQT member 4 Human genes 0.000 description 3
• 206010039897 Sedation Diseases 0.000 description 3
• 206010070834 Sensitisation Diseases 0.000 description 3
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
• 210000003169 central nervous system Anatomy 0.000 description 3
• 230000007812 deficiency Effects 0.000 description 3
• 238000003745 diagnosis Methods 0.000 description 3
• 238000012048 forced swim test Methods 0.000 description 3
• 125000000592 heterocycloalkyl group Chemical group 0.000 description 3
• 230000002401 inhibitory effect Effects 0.000 description 3
• 235000013336 milk Nutrition 0.000 description 3
• 210000004080 milk Anatomy 0.000 description 3
• 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
• 230000001537 neural effect Effects 0.000 description 3
• 210000002569 neuron Anatomy 0.000 description 3
• 230000036407 pain Effects 0.000 description 3
• 230000007310 pathophysiology Effects 0.000 description 3
• RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 3
• 230000000144 pharmacologic effect Effects 0.000 description 3
• 238000005086 pumping Methods 0.000 description 3
• 150000003222 pyridines Chemical class 0.000 description 3
• 150000003233 pyrroles Chemical class 0.000 description 3
• 230000036280 sedation Effects 0.000 description 3
• 230000001624 sedative effect Effects 0.000 description 3
• 230000008313 sensitization Effects 0.000 description 3
• 230000003997 social interaction Effects 0.000 description 3
• 238000011272 standard treatment Methods 0.000 description 3
• 231100000736 substance abuse Toxicity 0.000 description 3
• 229940124530 sulfonamide Drugs 0.000 description 3
• 150000003577 thiophenes Chemical class 0.000 description 3
• 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 2
• OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 2
• LIKMAJRDDDTEIG-UHFFFAOYSA-N 1-hexene Chemical compound CCCCC=C LIKMAJRDDDTEIG-UHFFFAOYSA-N 0.000 description 2
• MXWHAVQLNYKQMZ-UHFFFAOYSA-N 10,10,10-trifluorodecylbenzene Chemical compound FC(F)(F)CCCCCCCCCC1=CC=CC=C1 MXWHAVQLNYKQMZ-UHFFFAOYSA-N 0.000 description 2
• HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical compound C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 description 2
• CVICEEPAFUYBJG-UHFFFAOYSA-N 5-chloro-2,2-difluoro-1,3-benzodioxole Chemical group C1=C(Cl)C=C2OC(F)(F)OC2=C1 CVICEEPAFUYBJG-UHFFFAOYSA-N 0.000 description 2
• 208000017194 Affective disease Diseases 0.000 description 2
• 206010001497 Agitation Diseases 0.000 description 2
• 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 2
• 244000025254 Cannabis sativa Species 0.000 description 2
• 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 2
• 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 2
• XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
• 206010011878 Deafness Diseases 0.000 description 2
• 241000196324 Embryophyta Species 0.000 description 2
• 206010019070 Hallucination, auditory Diseases 0.000 description 2
• 101000994656 Homo sapiens Potassium voltage-gated channel subfamily KQT member 5 Proteins 0.000 description 2
• 208000001953 Hypotension Diseases 0.000 description 2
• WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 2
• 102000004310 Ion Channels Human genes 0.000 description 2
• 108090000862 Ion Channels Proteins 0.000 description 2
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
• 206010024870 Loss of libido Diseases 0.000 description 2
• 241001529936 Murinae Species 0.000 description 2
• 206010028347 Muscle twitching Diseases 0.000 description 2
• IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 2
• GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
• 102100034365 Potassium voltage-gated channel subfamily KQT member 5 Human genes 0.000 description 2
• 102000003946 Prolactin Human genes 0.000 description 2
• 108010057464 Prolactin Proteins 0.000 description 2
• XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
• QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 2
• WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
• 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
• 208000013200 Stress disease Diseases 0.000 description 2
• FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
• KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 2
• 230000005856 abnormality Effects 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 230000036982 action potential Effects 0.000 description 2
• 230000004913 activation Effects 0.000 description 2
• UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
• 125000001931 aliphatic group Chemical group 0.000 description 2
• 239000002269 analeptic agent Substances 0.000 description 2
• SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
• 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 2
• 230000004596 appetite loss Effects 0.000 description 2
• 230000003796 beauty Effects 0.000 description 2
• 238000009227 behaviour therapy Methods 0.000 description 2
• 230000001413 cellular effect Effects 0.000 description 2
• 230000000739 chaotic effect Effects 0.000 description 2
• 238000003776 cleavage reaction Methods 0.000 description 2
• 229960004170 clozapine Drugs 0.000 description 2
• QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 2
• 208000010877 cognitive disease Diseases 0.000 description 2
• 230000001276 controlling effect Effects 0.000 description 2
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
• NLUNLVTVUDIHFE-UHFFFAOYSA-N cyclooctylcyclooctane Chemical group C1CCCCCCC1C1CCCCCCC1 NLUNLVTVUDIHFE-UHFFFAOYSA-N 0.000 description 2
• 230000006378 damage Effects 0.000 description 2
• 231100000895 deafness Toxicity 0.000 description 2
• 238000011161 development Methods 0.000 description 2
• 208000002173 dizziness Diseases 0.000 description 2
• 210000005064 dopaminergic neuron Anatomy 0.000 description 2
• 230000004064 dysfunction Effects 0.000 description 2
• NVOFZLPWTFWFDQ-UHFFFAOYSA-N ethyl n-[2-amino-4-[(4-phenylanilino)methyl]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1CNC1=CC=C(C=2C=CC=CC=2)C=C1 NVOFZLPWTFWFDQ-UHFFFAOYSA-N 0.000 description 2
• 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 2
• 230000001605 fetal effect Effects 0.000 description 2
• 150000002240 furans Chemical class 0.000 description 2
• 230000002068 genetic effect Effects 0.000 description 2
• LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
• 208000016354 hearing loss disease Diseases 0.000 description 2
• 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• 230000036543 hypotension Effects 0.000 description 2
• 230000001976 improved effect Effects 0.000 description 2
• 238000000338 in vitro Methods 0.000 description 2
• 239000003112 inhibitor Substances 0.000 description 2
• 206010022437 insomnia Diseases 0.000 description 2
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
• 229910052744 lithium Inorganic materials 0.000 description 2
• 208000019017 loss of appetite Diseases 0.000 description 2
• 235000021266 loss of appetite Nutrition 0.000 description 2
• 238000004519 manufacturing process Methods 0.000 description 2
• 239000000463 material Substances 0.000 description 2
• 230000007246 mechanism Effects 0.000 description 2
• SLVMESMUVMCQIY-UHFFFAOYSA-N mesoridazine Chemical compound CN1CCCCC1CCN1C2=CC(S(C)=O)=CC=C2SC2=CC=CC=C21 SLVMESMUVMCQIY-UHFFFAOYSA-N 0.000 description 2
• 229960000300 mesoridazine Drugs 0.000 description 2
• 208000030159 metabolic disease Diseases 0.000 description 2
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
• WEVYAHXRMPXWCK-UHFFFAOYSA-N methyl cyanide Natural products CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
• 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 2
• 230000035772 mutation Effects 0.000 description 2
• 210000000933 neural crest Anatomy 0.000 description 2
• 229960002748 norepinephrine Drugs 0.000 description 2
• SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
• 150000002916 oxazoles Chemical class 0.000 description 2
• 230000002688 persistence Effects 0.000 description 2
• 239000008194 pharmaceutical composition Substances 0.000 description 2
• 239000011591 potassium Substances 0.000 description 2
• 229940097325 prolactin Drugs 0.000 description 2
• 235000018102 proteins Nutrition 0.000 description 2
• 102000004169 proteins and genes Human genes 0.000 description 2
• 229960004431 quetiapine Drugs 0.000 description 2
• URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 2
• 229960001534 risperidone Drugs 0.000 description 2
• RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 2
• 210000003296 saliva Anatomy 0.000 description 2
• 230000007017 scission Effects 0.000 description 2
• 230000035941 sexual motivation Effects 0.000 description 2
• 235000015170 shellfish Nutrition 0.000 description 2
• 239000007787 solid Substances 0.000 description 2
• 239000000021 stimulant Substances 0.000 description 2
• 239000004575 stone Substances 0.000 description 2
• 210000003523 substantia nigra Anatomy 0.000 description 2
• 229960004940 sulpiride Drugs 0.000 description 2
• 230000002459 sustained effect Effects 0.000 description 2
• 239000003826 tablet Substances 0.000 description 2
• 229940124597 therapeutic agent Drugs 0.000 description 2
• 150000003573 thiols Chemical class 0.000 description 2
• 229960002784 thioridazine Drugs 0.000 description 2
• WFPIAZLQTJBIFN-DVZOWYKESA-N zuclopenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(Cl)=CC=C2SC2=CC=CC=C2/1 WFPIAZLQTJBIFN-DVZOWYKESA-N 0.000 description 2
• SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
• XXCBVUVECFQJDZ-UHFFFAOYSA-N (2-methoxyphenyl) n-aminocarbamate Chemical compound COC1=CC=CC=C1OC(=O)NN XXCBVUVECFQJDZ-UHFFFAOYSA-N 0.000 description 1
• XFEVOHQZBADKOV-UHFFFAOYSA-N (2-methoxyphenyl) n-phenylcarbamate Chemical compound COC1=CC=CC=C1OC(=O)NC1=CC=CC=C1 XFEVOHQZBADKOV-UHFFFAOYSA-N 0.000 description 1
• JOFOMRLUUYVWQH-AXDSSHIGSA-N (2s)-2-amino-4-methyldecanoic acid Chemical compound CCCCCCC(C)C[C@H](N)C(O)=O JOFOMRLUUYVWQH-AXDSSHIGSA-N 0.000 description 1
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
• 125000006592 (C2-C3) alkenyl group Chemical group 0.000 description 1
• 125000006593 (C2-C3) alkynyl group Chemical group 0.000 description 1
• 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
• 125000006553 (C3-C8) cycloalkenyl group Chemical group 0.000 description 1
• VSWBSWWIRNCQIJ-GJZGRUSLSA-N (R,R)-asenapine Chemical compound O1C2=CC=CC=C2[C@@H]2CN(C)C[C@H]2C2=CC(Cl)=CC=C21 VSWBSWWIRNCQIJ-GJZGRUSLSA-N 0.000 description 1
• WSPOMRSOLSGNFJ-AUWJEWJLSA-N (Z)-chlorprothixene Chemical compound C1=C(Cl)C=C2C(=C/CCN(C)C)\C3=CC=CC=C3SC2=C1 WSPOMRSOLSGNFJ-AUWJEWJLSA-N 0.000 description 1
• GETTZEONDQJALK-UHFFFAOYSA-N (trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC=C1 GETTZEONDQJALK-UHFFFAOYSA-N 0.000 description 1
• UEMGWPRHOOEKTA-UHFFFAOYSA-N 1,3-difluorobenzene Chemical compound FC1=CC=CC(F)=C1 UEMGWPRHOOEKTA-UHFFFAOYSA-N 0.000 description 1
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
• IUVSEUFHPNITEQ-UHFFFAOYSA-N 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-[[5-(4-fluorophenyl)pyridin-3-yl]methyl]piperazine Chemical compound C1=CC(F)=CC=C1C1=CN=CC(CN2CCN(CC2)C=2C=3OCCOC=3C=CC=2)=C1 IUVSEUFHPNITEQ-UHFFFAOYSA-N 0.000 description 1
• DKMFBWQBDIGMHM-UHFFFAOYSA-N 1-(4-fluorophenyl)-4-(4-methyl-1-piperidinyl)-1-butanone Chemical compound C1CC(C)CCN1CCCC(=O)C1=CC=C(F)C=C1 DKMFBWQBDIGMHM-UHFFFAOYSA-N 0.000 description 1
• GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 description 1
• 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
• BYMZRMOOJUPLTH-UHFFFAOYSA-N 1h-indol-2-ylhydrazine Chemical compound C1=CC=C2NC(NN)=CC2=C1 BYMZRMOOJUPLTH-UHFFFAOYSA-N 0.000 description 1
• 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
• DZGMFITYAJIDHR-UHFFFAOYSA-N 2,3-dihydro-1h-indene-1-carboxamide Chemical compound C1=CC=C2C(C(=O)N)CCC2=C1 DZGMFITYAJIDHR-UHFFFAOYSA-N 0.000 description 1
• LPDVJOCWBDEEEW-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[1-[(4-fluorophenyl)methyl]-2,3-dihydroindol-5-yl]acetamide Chemical compound C1=CC(F)=CC=C1CN1C2=CC=C(NC(=O)CC=3C=CC(F)=CC=3)C=C2CC1 LPDVJOCWBDEEEW-UHFFFAOYSA-N 0.000 description 1
• CSEQTDRDZQLHLC-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[6-nitro-1-[[4-(trifluoromethyl)phenyl]methyl]-2,3-dihydroindol-5-yl]acetamide Chemical compound C1CC=2C=C(NC(=O)CC=3C=CC(F)=CC=3)C([N+](=O)[O-])=CC=2N1CC1=CC=C(C(F)(F)F)C=C1 CSEQTDRDZQLHLC-UHFFFAOYSA-N 0.000 description 1
• HUPVBFQYJHFONM-UHFFFAOYSA-N 2-(4-fluorophenyl)acetamide Chemical compound NC(=O)CC1=CC=C(F)C=C1 HUPVBFQYJHFONM-UHFFFAOYSA-N 0.000 description 1
• VHQJOTSBQJDZBA-UHFFFAOYSA-N 2-(5-chlorothiophen-2-yl)-1H-indole Chemical compound S1C(Cl)=CC=C1C1=CC2=CC=CC=C2N1 VHQJOTSBQJDZBA-UHFFFAOYSA-N 0.000 description 1
• AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
• XUNJEPMTPOXYEW-UHFFFAOYSA-N 2-[(4-nitrophenyl)methoxycarbonyl]benzoic acid Chemical compound C1=CC=C(C(=C1)C(=O)O)C(=O)OCC2=CC=C(C=C2)[N+](=O)[O-] XUNJEPMTPOXYEW-UHFFFAOYSA-N 0.000 description 1
• BABFYCSPNDKXRI-UHFFFAOYSA-N 2-[4-[3-(2-chlorophenothiazin-10-yl)propyl]piperazin-1-yl]ethyl 4-aminobutanoate Chemical compound C1CN(CCOC(=O)CCCN)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 BABFYCSPNDKXRI-UHFFFAOYSA-N 0.000 description 1
• MCLACVSXIIOHHO-UHFFFAOYSA-N 2-anilinooxycarbonylbenzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)ONC1=CC=CC=C1 MCLACVSXIIOHHO-UHFFFAOYSA-N 0.000 description 1
• IQHSSYROJYPFDV-UHFFFAOYSA-N 2-bromo-1,3-dichloro-5-(trifluoromethyl)benzene Chemical group FC(F)(F)C1=CC(Cl)=C(Br)C(Cl)=C1 IQHSSYROJYPFDV-UHFFFAOYSA-N 0.000 description 1
• GSFNQBFZFXUTBN-UHFFFAOYSA-N 2-chlorothiophene Chemical compound ClC1=CC=CS1 GSFNQBFZFXUTBN-UHFFFAOYSA-N 0.000 description 1
• UDQPWRNCCSSDOQ-UHFFFAOYSA-N 2-cyclopentyl-n-[2,6-dimethyl-4-[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]phenyl]acetamide Chemical compound C=1C(C)=C(NC(=O)CC2CCCC2)C(C)=CC=1N(C)CC1=CC=C(C(F)(F)F)C=C1 UDQPWRNCCSSDOQ-UHFFFAOYSA-N 0.000 description 1
• QZCCCEGFZZERCR-UHFFFAOYSA-N 2-cyclopentyl-n-[4-[(3-fluoroanilino)methyl]-2,6-dimethylphenyl]acetamide Chemical compound C=1C(C)=C(NC(=O)CC2CCCC2)C(C)=CC=1CNC1=CC=CC(F)=C1 QZCCCEGFZZERCR-UHFFFAOYSA-N 0.000 description 1
• XSUPXKHTYKPZKM-UHFFFAOYSA-N 2-hydroxy-4-oxo-2-(2-oxo-2-propoxyethyl)-4-propoxybutanoic acid Chemical compound CCCOC(=O)CC(O)(C(O)=O)CC(=O)OCCC XSUPXKHTYKPZKM-UHFFFAOYSA-N 0.000 description 1
• AOPRXJXHLWYPQR-UHFFFAOYSA-N 2-phenoxyacetamide Chemical compound NC(=O)COC1=CC=CC=C1 AOPRXJXHLWYPQR-UHFFFAOYSA-N 0.000 description 1
• WTBJKSFAEWHLCQ-UHFFFAOYSA-N 2-phenylcyclopropene-1-carboxylic acid Chemical compound C1C(C(=O)O)=C1C1=CC=CC=C1 WTBJKSFAEWHLCQ-UHFFFAOYSA-N 0.000 description 1
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
• VVYOXVXPNLGNFB-UHFFFAOYSA-N 3-[1-[(5-chlorothiophen-2-yl)methyl]-2,3-dihydroindol-5-yl]-1-methyl-1-propylurea Chemical compound C1CC2=CC(NC(=O)N(C)CCC)=CC=C2N1CC1=CC=C(Cl)S1 VVYOXVXPNLGNFB-UHFFFAOYSA-N 0.000 description 1
• FEBOTPHFXYHVPL-UHFFFAOYSA-N 3-[1-[4-(4-fluorophenyl)-4-oxobutyl]-4-piperidinyl]-1H-benzimidazol-2-one Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 FEBOTPHFXYHVPL-UHFFFAOYSA-N 0.000 description 1
• IYGAMTQMILRCCI-UHFFFAOYSA-N 3-aminopropane-1-thiol Chemical compound NCCCS IYGAMTQMILRCCI-UHFFFAOYSA-N 0.000 description 1
• GUJRSXAPGDDABA-NSHDSACASA-N 3-bromo-N-[[(2S)-1-ethyl-2-pyrrolidinyl]methyl]-2,6-dimethoxybenzamide Chemical compound CCN1CCC[C@H]1CNC(=O)C1=C(OC)C=CC(Br)=C1OC GUJRSXAPGDDABA-NSHDSACASA-N 0.000 description 1
• BIAVGWDGIJKWRM-FQEVSTJZSA-N 3-hydroxy-2-phenyl-n-[(1s)-1-phenylpropyl]quinoline-4-carboxamide Chemical compound N([C@@H](CC)C=1C=CC=CC=1)C(=O)C(C1=CC=CC=C1N=1)=C(O)C=1C1=CC=CC=C1 BIAVGWDGIJKWRM-FQEVSTJZSA-N 0.000 description 1
• PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 description 1
• ACMJJQYSPUPMPN-UHFFFAOYSA-N 4-chloro-3-fluoroaniline Chemical compound NC1=CC=C(Cl)C(F)=C1 ACMJJQYSPUPMPN-UHFFFAOYSA-N 0.000 description 1
• RJWBTWIBUIGANW-UHFFFAOYSA-N 4-chlorobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Cl)C=C1 RJWBTWIBUIGANW-UHFFFAOYSA-N 0.000 description 1
• 125000002528 4-isopropyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• FTVHMXRCGNWCOL-UHFFFAOYSA-N 5-fluoro-1-benzofuran Chemical compound FC1=CC=C2OC=CC2=C1 FTVHMXRCGNWCOL-UHFFFAOYSA-N 0.000 description 1
• ZKBQDFAWXLTYKS-UHFFFAOYSA-N 6-Chloro-1H-purine Chemical compound ClC1=NC=NC2=C1NC=N2 ZKBQDFAWXLTYKS-UHFFFAOYSA-N 0.000 description 1
• VATIMCNDILNPMW-UHFFFAOYSA-N 7-chloro-1h-diazepine Chemical compound ClC1=CC=CC=NN1 VATIMCNDILNPMW-UHFFFAOYSA-N 0.000 description 1
• QOYHHIBFXOOADH-UHFFFAOYSA-N 8-[4,4-bis(4-fluorophenyl)butyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 QOYHHIBFXOOADH-UHFFFAOYSA-N 0.000 description 1
• 102100037651 AP-2 complex subunit sigma Human genes 0.000 description 1
• HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
• NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
• 108060003345 Adrenergic Receptor Proteins 0.000 description 1
• 102000017910 Adrenergic receptor Human genes 0.000 description 1
• 206010067484 Adverse reaction Diseases 0.000 description 1
• 201000000736 Amenorrhea Diseases 0.000 description 1
• 206010001928 Amenorrhoea Diseases 0.000 description 1
• 208000000044 Amnesia Diseases 0.000 description 1
• 208000031091 Amnestic disease Diseases 0.000 description 1
• 208000019901 Anxiety disease Diseases 0.000 description 1
• CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 1
• 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
• 241001674044 Blattodea Species 0.000 description 1
• RKLNONIVDFXQRX-UHFFFAOYSA-N Bromperidol Chemical compound C1CC(O)(C=2C=CC(Br)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 RKLNONIVDFXQRX-UHFFFAOYSA-N 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
• HZLUTGWQUUSMGM-UHFFFAOYSA-N C(CCCCCCCCC)(=O)O.C1CC1 Chemical compound C(CCCCCCCCC)(=O)O.C1CC1 HZLUTGWQUUSMGM-UHFFFAOYSA-N 0.000 description 1
• GYFFFQARBGCVMH-UHFFFAOYSA-N C(CCCCCCCCC)(=O)O.C1CCC1 Chemical compound C(CCCCCCCCC)(=O)O.C1CCC1 GYFFFQARBGCVMH-UHFFFAOYSA-N 0.000 description 1
• OXDWVDQDBZVJNS-UHFFFAOYSA-N C1=COC(=CO1)CCCCCCCCCC(=O)O Chemical compound C1=COC(=CO1)CCCCCCCCCC(=O)O OXDWVDQDBZVJNS-UHFFFAOYSA-N 0.000 description 1
• 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
• 125000003320 C2-C6 alkenyloxy group Chemical group 0.000 description 1
• 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 1
• GBPVBHNUTXSJHB-UHFFFAOYSA-N CCCCNC1=C(C=C(C=C1)CNC2=CC(=C(C=C2)Cl)Cl)F Chemical compound CCCCNC1=C(C=C(C=C1)CNC2=CC(=C(C=C2)Cl)Cl)F GBPVBHNUTXSJHB-UHFFFAOYSA-N 0.000 description 1
• RJSBNMCCIHVJAB-UHFFFAOYSA-N CCCCNC1=C(C=C(C=C1)CNC2=CC=C(C=C2)Cl)Cl Chemical compound CCCCNC1=C(C=C(C=C1)CNC2=CC=C(C=C2)Cl)Cl RJSBNMCCIHVJAB-UHFFFAOYSA-N 0.000 description 1
• SNQSMXRDBVSCPV-UHFFFAOYSA-N CCCCNC1=C(C=C(C=C1)CNC2=CC=C(C=C2)Cl)F Chemical compound CCCCNC1=C(C=C(C=C1)CNC2=CC=C(C=C2)Cl)F SNQSMXRDBVSCPV-UHFFFAOYSA-N 0.000 description 1
• RYWKALSYXJDVHO-UHFFFAOYSA-N CCCCNC1=CC=C(C=C1)CNC2=CC=C(C=C2)Cl Chemical compound CCCCNC1=CC=C(C=C1)CNC2=CC=C(C=C2)Cl RYWKALSYXJDVHO-UHFFFAOYSA-N 0.000 description 1
• MYQYENDNAQWHAJ-UHFFFAOYSA-N CCOC(=O)NC1=C(C=C(C=C1)NCC2=C(C(=CS2)Br)C3=CC4=CC=CC=C4N3)N Chemical compound CCOC(=O)NC1=C(C=C(C=C1)NCC2=C(C(=CS2)Br)C3=CC4=CC=CC=C4N3)N MYQYENDNAQWHAJ-UHFFFAOYSA-N 0.000 description 1
• ANDGGVOPIJEHOF-UHFFFAOYSA-N CX-516 Chemical compound C=1C=C2N=CC=NC2=CC=1C(=O)N1CCCCC1 ANDGGVOPIJEHOF-UHFFFAOYSA-N 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• UJOBWOGCFQCDNV-UHFFFAOYSA-N Carbazole Natural products C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 1
• 102000034573 Channels Human genes 0.000 description 1
• OMPIYDSYGYKWSG-UHFFFAOYSA-N Citronensaeure-alpha-aethylester Natural products CCOC(=O)CC(O)(C(O)=O)CC(O)=O OMPIYDSYGYKWSG-UHFFFAOYSA-N 0.000 description 1
• 241000252185 Cobitidae Species 0.000 description 1
• 208000028698 Cognitive impairment Diseases 0.000 description 1
• 244000163122 Curcuma domestica Species 0.000 description 1
• 235000003392 Curcuma domestica Nutrition 0.000 description 1
• HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
• ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 description 1
• ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 description 1
• 206010011882 Deafness congenital Diseases 0.000 description 1
• 206010012335 Dependence Diseases 0.000 description 1
• 206010012374 Depressed mood Diseases 0.000 description 1
• 206010054089 Depressive symptom Diseases 0.000 description 1
• 206010012735 Diarrhoea Diseases 0.000 description 1
• MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
• 229940096895 Dopamine D2 receptor agonist Drugs 0.000 description 1
• 208000017701 Endocrine disease Diseases 0.000 description 1
• 206010015150 Erythema Diseases 0.000 description 1
• PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 1
• 208000001287 Galactorrhea Diseases 0.000 description 1
• 206010017600 Galactorrhoea Diseases 0.000 description 1
• 206010064571 Gene mutation Diseases 0.000 description 1
• 101800001586 Ghrelin Proteins 0.000 description 1
• 102400000442 Ghrelin-28 Human genes 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• INJOMKTZOLKMBF-UHFFFAOYSA-N Guanfacine Chemical compound NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl INJOMKTZOLKMBF-UHFFFAOYSA-N 0.000 description 1
• 208000016621 Hearing disease Diseases 0.000 description 1
• 241000162682 Heterogen Species 0.000 description 1
• 102000000543 Histamine Receptors Human genes 0.000 description 1
• 108010002059 Histamine Receptors Proteins 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101000806914 Homo sapiens AP-2 complex subunit sigma Proteins 0.000 description 1
• 101000974726 Homo sapiens Potassium voltage-gated channel subfamily E member 1 Proteins 0.000 description 1
• RAXXELZNTBOGNW-UHFFFAOYSA-O Imidazolium Chemical compound C1=C[NH+]=CN1 RAXXELZNTBOGNW-UHFFFAOYSA-O 0.000 description 1
• 206010049976 Impatience Diseases 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 206010022489 Insulin Resistance Diseases 0.000 description 1
• XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
• 108010011185 KCNQ1 Potassium Channel Proteins 0.000 description 1
• WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• 241000283986 Lepus Species 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• 208000026139 Memory disease Diseases 0.000 description 1
• DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 1
• 208000019695 Migraine disease Diseases 0.000 description 1
• 241000699670 Mus sp. Species 0.000 description 1
• JTVPZMFULRWINT-UHFFFAOYSA-N N-[2-(diethylamino)ethyl]-2-methoxy-5-methylsulfonylbenzamide Chemical compound CCN(CC)CCNC(=O)C1=CC(S(C)(=O)=O)=CC=C1OC JTVPZMFULRWINT-UHFFFAOYSA-N 0.000 description 1
• JNNOSTQEZICQQP-UHFFFAOYSA-N N-desmethylclozapine Chemical compound N=1C2=CC(Cl)=CC=C2NC2=CC=CC=C2C=1N1CCNCC1 JNNOSTQEZICQQP-UHFFFAOYSA-N 0.000 description 1
• LFIVMRIAUODNCZ-UHFFFAOYSA-N NN.N#CC#N Chemical compound NN.N#CC#N LFIVMRIAUODNCZ-UHFFFAOYSA-N 0.000 description 1
• 229910002651 NO3 Inorganic materials 0.000 description 1
• 206010028813 Nausea Diseases 0.000 description 1
• 208000012902 Nervous system disease Diseases 0.000 description 1
• 206010029216 Nervousness Diseases 0.000 description 1
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
• ZZQNEJILGNNOEP-UHFFFAOYSA-N Ocaperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC3=C(C)N=C4N(C3=O)C=CC=C4C)=NOC2=C1 ZZQNEJILGNNOEP-UHFFFAOYSA-N 0.000 description 1
• 206010033557 Palpitations Diseases 0.000 description 1
• 244000131316 Panax pseudoginseng Species 0.000 description 1
• 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
• 235000003140 Panax quinquefolius Nutrition 0.000 description 1
• 206010033799 Paralysis Diseases 0.000 description 1
• 206010033864 Paranoia Diseases 0.000 description 1
• 208000027099 Paranoid disease Diseases 0.000 description 1
• RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 1
• 244000046052 Phaseolus vulgaris Species 0.000 description 1
• 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
• 102100022755 Potassium voltage-gated channel subfamily E member 1 Human genes 0.000 description 1
• 102100037444 Potassium voltage-gated channel subfamily KQT member 1 Human genes 0.000 description 1
• ZGUGWUXLJSTTMA-UHFFFAOYSA-N Promazinum Chemical compound C1=CC=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZGUGWUXLJSTTMA-UHFFFAOYSA-N 0.000 description 1
• 208000029808 Psychomotor disease Diseases 0.000 description 1
• 206010037249 Psychotic behaviour Diseases 0.000 description 1
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
• 241000700159 Rattus Species 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 208000008409 Romano-Ward Syndrome Diseases 0.000 description 1
• 206010039424 Salivary hypersecretion Diseases 0.000 description 1
• 208000020114 Schizophrenia and other psychotic disease Diseases 0.000 description 1
• 208000036750 Schizophrenia, residual type Diseases 0.000 description 1
• 241000239226 Scorpiones Species 0.000 description 1
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
• 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
• 206010042464 Suicide attempt Diseases 0.000 description 1
• UNRHXEPDKXPRTM-UHFFFAOYSA-N Sultopride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=CC=C1OC UNRHXEPDKXPRTM-UHFFFAOYSA-N 0.000 description 1
• GFBKORZTTCHDGY-UWVJOHFNSA-N Thiothixene Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2\C1=C\CCN1CCN(C)CC1 GFBKORZTTCHDGY-UWVJOHFNSA-N 0.000 description 1
• 206010044565 Tremor Diseases 0.000 description 1
• 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
• GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical group OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
• DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
• 206010047513 Vision blurred Diseases 0.000 description 1
• 206010048010 Withdrawal syndrome Diseases 0.000 description 1
• LONQTZORWVBHMK-UHFFFAOYSA-N [N].NN Chemical group [N].NN LONQTZORWVBHMK-UHFFFAOYSA-N 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 229960005054 acepromazine Drugs 0.000 description 1
• NOSIYYJFMPDDSA-UHFFFAOYSA-N acepromazine Chemical compound C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 NOSIYYJFMPDDSA-UHFFFAOYSA-N 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
• 229960000276 acetophenazine Drugs 0.000 description 1
• WNTYBHLDCKXEOT-UHFFFAOYSA-N acetophenazine Chemical compound C12=CC(C(=O)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(CCO)CC1 WNTYBHLDCKXEOT-UHFFFAOYSA-N 0.000 description 1
• 101150109352 acr-16 gene Proteins 0.000 description 1
• 239000012190 activator Substances 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 230000000996 additive effect Effects 0.000 description 1
• 239000000674 adrenergic antagonist Substances 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 230000006838 adverse reaction Effects 0.000 description 1
• 230000008484 agonism Effects 0.000 description 1
• 125000003158 alcohol group Chemical group 0.000 description 1
• 125000005741 alkyl alkenyl group Chemical group 0.000 description 1
• 125000005087 alkynylcarbonyl group Chemical group 0.000 description 1
• 231100000540 amenorrhea Toxicity 0.000 description 1
• 235000001014 amino acid Nutrition 0.000 description 1
• 150000001413 amino acids Chemical class 0.000 description 1
• 229940124277 aminobutyric acid Drugs 0.000 description 1
• 229960003036 amisulpride Drugs 0.000 description 1
• NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 description 1
• 230000006986 amnesia Effects 0.000 description 1
• 210000004102 animal cell Anatomy 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 1
• 230000000469 anti-sperm effect Effects 0.000 description 1
• 229940125681 anticonvulsant agent Drugs 0.000 description 1
• 239000002220 antihypertensive agent Substances 0.000 description 1
• 229940030600 antihypertensive agent Drugs 0.000 description 1
• 239000000228 antimanic agent Substances 0.000 description 1
• 230000036506 anxiety Effects 0.000 description 1
• 229960004372 aripiprazole Drugs 0.000 description 1
• 230000037007 arousal Effects 0.000 description 1
• 206010003119 arrhythmia Diseases 0.000 description 1
• 230000006793 arrhythmia Effects 0.000 description 1
• 125000005129 aryl carbonyl group Chemical group 0.000 description 1
• 229960005245 asenapine Drugs 0.000 description 1
• 239000003693 atypical antipsychotic agent Substances 0.000 description 1
• 229940127236 atypical antipsychotics Drugs 0.000 description 1
• 150000003976 azacycloalkanes Chemical class 0.000 description 1
• ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• 201000003452 benign familial neonatal epilepsy Diseases 0.000 description 1
• 201000010295 benign neonatal seizures Diseases 0.000 description 1
• 229960002507 benperidol Drugs 0.000 description 1
• 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• 125000002527 bicyclic carbocyclic group Chemical group 0.000 description 1
• 230000007321 biological mechanism Effects 0.000 description 1
• 230000005540 biological transmission Effects 0.000 description 1
• 208000022257 bipolar II disease Diseases 0.000 description 1
• 229910052797 bismuth Inorganic materials 0.000 description 1
• 208000030270 breast disease Diseases 0.000 description 1
• UJMLUDDDFVWQIY-UHFFFAOYSA-N bromohydrazine Chemical compound NNBr UJMLUDDDFVWQIY-UHFFFAOYSA-N 0.000 description 1
• 229960004037 bromperidol Drugs 0.000 description 1
• BEUYFMPBZRYBJK-UHFFFAOYSA-N butane-1-sulfonic acid Chemical compound CC[CH]CS(O)(=O)=O BEUYFMPBZRYBJK-UHFFFAOYSA-N 0.000 description 1
• 229960000608 butaperazine Drugs 0.000 description 1
• DVLBYTMYSMAKHP-UHFFFAOYSA-N butaperazine Chemical compound C12=CC(C(=O)CCC)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(C)CC1 DVLBYTMYSMAKHP-UHFFFAOYSA-N 0.000 description 1
• 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 230000001914 calming effect Effects 0.000 description 1
• 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
• 229910002091 carbon monoxide Inorganic materials 0.000 description 1
• 230000000747 cardiac effect Effects 0.000 description 1
• KPWSJANDNDDRMB-QAQDUYKDSA-N cariprazine Chemical compound C1C[C@@H](NC(=O)N(C)C)CC[C@@H]1CCN1CCN(C=2C(=C(Cl)C=CC=2)Cl)CC1 KPWSJANDNDDRMB-QAQDUYKDSA-N 0.000 description 1
• 229960005123 cariprazine Drugs 0.000 description 1
• 150000001768 cations Chemical class 0.000 description 1
• 210000005056 cell body Anatomy 0.000 description 1
• SFZULDYEOVSIKM-UHFFFAOYSA-N chembl321317 Chemical compound C1=CC(C(=N)NO)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(=N)NO)O1 SFZULDYEOVSIKM-UHFFFAOYSA-N 0.000 description 1
• 238000006243 chemical reaction Methods 0.000 description 1
• 150000001805 chlorine compounds Chemical class 0.000 description 1
• 229960003030 chlorproethazine Drugs 0.000 description 1
• DBOUGBAQLIXZLV-UHFFFAOYSA-N chlorproethazine Chemical compound C1=C(Cl)C=C2N(CCCN(CC)CC)C3=CC=CC=C3SC2=C1 DBOUGBAQLIXZLV-UHFFFAOYSA-N 0.000 description 1
• 229960001076 chlorpromazine Drugs 0.000 description 1
• ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
• 229960001552 chlorprothixene Drugs 0.000 description 1
• 231100000749 chronicity Toxicity 0.000 description 1
• 210000000078 claw Anatomy 0.000 description 1
• 229960001184 clopenthixol Drugs 0.000 description 1
• 210000003477 cochlea Anatomy 0.000 description 1
• 230000007278 cognition impairment Effects 0.000 description 1
• 230000003920 cognitive function Effects 0.000 description 1
• 238000002648 combination therapy Methods 0.000 description 1
• 230000000052 comparative effect Effects 0.000 description 1
• 229940125904 compound 1 Drugs 0.000 description 1
• 235000009508 confectionery Nutrition 0.000 description 1
• 229910052802 copper Inorganic materials 0.000 description 1
• 230000008878 coupling Effects 0.000 description 1
• 238000010168 coupling process Methods 0.000 description 1
• 238000005859 coupling reaction Methods 0.000 description 1
• 235000003373 curcuma longa Nutrition 0.000 description 1
• 229960004278 cyamemazine Drugs 0.000 description 1
• SLFGIOIONGJGRT-UHFFFAOYSA-N cyamemazine Chemical compound C1=C(C#N)C=C2N(CC(CN(C)C)C)C3=CC=CC=C3SC2=C1 SLFGIOIONGJGRT-UHFFFAOYSA-N 0.000 description 1
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• ARUKYTASOALXFG-UHFFFAOYSA-N cycloheptylcycloheptane Chemical group C1CCCCCC1C1CCCCCC1 ARUKYTASOALXFG-UHFFFAOYSA-N 0.000 description 1
• 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
• 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
• LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentenylidene Natural products C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 1
• YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 description 1
• 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
• 125000003493 decenyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• 125000005070 decynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 229960000632 dexamfetamine Drugs 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• DXVWRJRZCMCNEU-UHFFFAOYSA-N dimercaptoamine Chemical compound SNS DXVWRJRZCMCNEU-UHFFFAOYSA-N 0.000 description 1
• 229910001882 dioxygen Inorganic materials 0.000 description 1
• 208000037765 diseases and disorders Diseases 0.000 description 1
• 238000002224 dissection Methods 0.000 description 1
• 229930004069 diterpene Natural products 0.000 description 1
• 150000004141 diterpene derivatives Chemical class 0.000 description 1
• 239000002934 diuretic Substances 0.000 description 1
• 230000001882 diuretic effect Effects 0.000 description 1
• 229960005146 dixyrazine Drugs 0.000 description 1
• MSYUMPGNGDNTIQ-UHFFFAOYSA-N dixyrazine Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1CC(C)CN1CCN(CCOCCO)CC1 MSYUMPGNGDNTIQ-UHFFFAOYSA-N 0.000 description 1
• 239000002288 dopamine 2 receptor stimulating agent Substances 0.000 description 1
• 229960000394 droperidol Drugs 0.000 description 1
• RMEDXOLNCUSCGS-UHFFFAOYSA-N droperidol Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC=C(N2C(NC3=CC=CC=C32)=O)CC1 RMEDXOLNCUSCGS-UHFFFAOYSA-N 0.000 description 1
• 230000009977 dual effect Effects 0.000 description 1
• 208000024732 dysthymic disease Diseases 0.000 description 1
• 230000005611 electricity Effects 0.000 description 1
• VAIOZOCLKVMIMN-PRJWTAEASA-N eplivanserin Chemical compound C=1C=CC=C(F)C=1\C(=N/OCCN(C)C)\C=C\C1=CC=C(O)C=C1 VAIOZOCLKVMIMN-PRJWTAEASA-N 0.000 description 1
• 229950000789 eplivanserin Drugs 0.000 description 1
• AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
• 229940057975 ethyl citrate Drugs 0.000 description 1
• WALRLVHHRQJWMT-UHFFFAOYSA-N ethyl n-[2-amino-4-(thiophen-3-ylmethylamino)phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CSC=C1 WALRLVHHRQJWMT-UHFFFAOYSA-N 0.000 description 1
• RAVCWWJMYAMNLK-UHFFFAOYSA-N ethyl n-[2-amino-4-[(3-fluoroanilino)methyl]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1CNC1=CC=CC(F)=C1 RAVCWWJMYAMNLK-UHFFFAOYSA-N 0.000 description 1
• RNFBDOBYXLGUBY-UHFFFAOYSA-N ethyl n-[2-amino-4-[(3-methylanilino)methyl]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1CNC1=CC=CC(C)=C1 RNFBDOBYXLGUBY-UHFFFAOYSA-N 0.000 description 1
• DWSPCTCHYKCYFR-UHFFFAOYSA-N ethyl n-[2-amino-4-[(4-chloroanilino)methyl]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1CNC1=CC=C(Cl)C=C1 DWSPCTCHYKCYFR-UHFFFAOYSA-N 0.000 description 1
• AEBTUIWNDWVQNE-UHFFFAOYSA-N ethyl n-[2-amino-4-[[3-(trifluoromethyl)anilino]methyl]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1CNC1=CC=CC(C(F)(F)F)=C1 AEBTUIWNDWVQNE-UHFFFAOYSA-N 0.000 description 1
• PJQJLRQLLHQJMP-UHFFFAOYSA-N ethyl n-[2-chloro-4-[(3,4-dichloroanilino)methyl]phenyl]carbamate Chemical compound C1=C(Cl)C(NC(=O)OCC)=CC=C1CNC1=CC=C(Cl)C(Cl)=C1 PJQJLRQLLHQJMP-UHFFFAOYSA-N 0.000 description 1
• DTOYTZIERSGENB-UHFFFAOYSA-N ethyl n-[4-(1-benzothiophen-3-ylmethylamino)-2-cyclopentyloxyphenyl]carbamate Chemical compound CCOC(=O)NC1=CC=C(NCC=2C3=CC=CC=C3SC=2)C=C1OC1CCCC1 DTOYTZIERSGENB-UHFFFAOYSA-N 0.000 description 1
• XDKSFHCRKBLVPN-UHFFFAOYSA-N ethyl n-[4-[(2,4-difluorophenyl)methylamino]-2-methoxyphenyl]carbamate Chemical compound C1=C(OC)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1F XDKSFHCRKBLVPN-UHFFFAOYSA-N 0.000 description 1
• LCEODKNUZATZLW-UHFFFAOYSA-N ethyl n-[4-[(3-methoxyphenyl)methylamino]-2-phenylmethoxyphenyl]carbamate Chemical compound C1=C(OCC=2C=CC=CC=2)C(NC(=O)OCC)=CC=C1NCC1=CC=CC(OC)=C1 LCEODKNUZATZLW-UHFFFAOYSA-N 0.000 description 1
• JHNNJXNHEUWQQI-UHFFFAOYSA-N ethyl n-[4-[(4-tert-butylphenyl)methylamino]-2-(trifluoromethyl)phenyl]carbamate Chemical compound C1=C(C(F)(F)F)C(NC(=O)OCC)=CC=C1NCC1=CC=C(C(C)(C)C)C=C1 JHNNJXNHEUWQQI-UHFFFAOYSA-N 0.000 description 1
• GZXSDYYWLZERLF-UHFFFAOYSA-N ethyl n-ethylcarbamate Chemical compound CCNC(=O)OCC GZXSDYYWLZERLF-UHFFFAOYSA-N 0.000 description 1
• ZHMIEJHAMNTUBZ-UHFFFAOYSA-N ethyl n-phenyl-n-propylcarbamate Chemical compound CCOC(=O)N(CCC)C1=CC=CC=C1 ZHMIEJHAMNTUBZ-UHFFFAOYSA-N 0.000 description 1
• 125000005469 ethylenyl group Chemical group 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 208000015700 familial long QT syndrome Diseases 0.000 description 1
• XFVRBYKKGGDPAJ-UHFFFAOYSA-N farampator Chemical compound C1=CC2=NON=C2C=C1C(=O)N1CCCCC1 XFVRBYKKGGDPAJ-UHFFFAOYSA-N 0.000 description 1
• 229950010629 farampator Drugs 0.000 description 1
• 238000010304 firing Methods 0.000 description 1
• 229960005220 fluanisone Drugs 0.000 description 1
• IRYFCWPNDIUQOW-UHFFFAOYSA-N fluanisone Chemical compound COC1=CC=CC=C1N1CCN(CCCC(=O)C=2C=CC(F)=CC=2)CC1 IRYFCWPNDIUQOW-UHFFFAOYSA-N 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 125000001207 fluorophenyl group Chemical group 0.000 description 1
• 229960002690 fluphenazine Drugs 0.000 description 1
• 229960003532 fluspirilene Drugs 0.000 description 1
• GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 description 1
• 235000008434 ginseng Nutrition 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 229930195712 glutamate Natural products 0.000 description 1
• 229960002449 glycine Drugs 0.000 description 1
• 229960002048 guanfacine Drugs 0.000 description 1
• 210000002768 hair cell Anatomy 0.000 description 1
• 229960003878 haloperidol Drugs 0.000 description 1
• 231100000304 hepatotoxicity Toxicity 0.000 description 1
• DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
• 125000004366 heterocycloalkenyl group Chemical group 0.000 description 1
• 125000006038 hexenyl group Chemical group 0.000 description 1
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000005980 hexynyl group Chemical group 0.000 description 1
• 210000004295 hippocampal neuron Anatomy 0.000 description 1
• 210000001320 hippocampus Anatomy 0.000 description 1
• 210000005260 human cell Anatomy 0.000 description 1
• 150000002429 hydrazines Chemical class 0.000 description 1
• 229960003162 iloperidone Drugs 0.000 description 1
• XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical compound COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 description 1
• 230000002779 inactivation Effects 0.000 description 1
• 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 1
• 230000036512 infertility Effects 0.000 description 1
• 208000000509 infertility Diseases 0.000 description 1
• 231100000535 infertility Toxicity 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 229910052740 iodine Inorganic materials 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 229910052741 iridium Inorganic materials 0.000 description 1
• GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 1
• 150000002576 ketones Chemical class 0.000 description 1
• 210000003127 knee Anatomy 0.000 description 1
• 229910052747 lanthanoid Inorganic materials 0.000 description 1
• 150000002602 lanthanoids Chemical class 0.000 description 1
• 210000002414 leg Anatomy 0.000 description 1
• 201000002364 leukopenia Diseases 0.000 description 1
• 231100001022 leukopenia Toxicity 0.000 description 1
• 229960004145 levosulpiride Drugs 0.000 description 1
• 210000003715 limbic system Anatomy 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 230000007056 liver toxicity Effects 0.000 description 1
• 201000006908 long QT syndrome 1 Diseases 0.000 description 1
• 229960001432 lurasidone Drugs 0.000 description 1
• PQXKDMSYBGKCJA-CVTJIBDQSA-N lurasidone Chemical compound C1=CC=C2C(N3CCN(CC3)C[C@@H]3CCCC[C@H]3CN3C(=O)[C@@H]4[C@H]5CC[C@H](C5)[C@@H]4C3=O)=NSC2=C1 PQXKDMSYBGKCJA-CVTJIBDQSA-N 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 229960001861 melperone Drugs 0.000 description 1
• 239000012528 membrane Substances 0.000 description 1
• 230000017813 membrane repolarization Effects 0.000 description 1
• 206010027175 memory impairment Diseases 0.000 description 1
• 208000007106 menorrhagia Diseases 0.000 description 1
• 230000004630 mental health Effects 0.000 description 1
• 210000001259 mesencephalon Anatomy 0.000 description 1
• FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 description 1
• 229940042053 methotrimeprazine Drugs 0.000 description 1
• VRQVVMDWGGWHTJ-CQSZACIVSA-N methotrimeprazine Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1 VRQVVMDWGGWHTJ-CQSZACIVSA-N 0.000 description 1
• GIOTXFVSHZODRM-UHFFFAOYSA-N methyl 4-[[3-methyl-4-(propoxycarbonylamino)anilino]methyl]benzoate Chemical compound C1=C(C)C(NC(=O)OCCC)=CC=C1NCC1=CC=C(C(=O)OC)C=C1 GIOTXFVSHZODRM-UHFFFAOYSA-N 0.000 description 1
• 229960001344 methylphenidate Drugs 0.000 description 1
• 206010027599 migraine Diseases 0.000 description 1
• 238000012544 monitoring process Methods 0.000 description 1
• 239000004050 mood stabilizer Substances 0.000 description 1
• 229940127237 mood stabilizer Drugs 0.000 description 1
• 229960000758 moperone Drugs 0.000 description 1
• AGAHNABIDCTLHW-UHFFFAOYSA-N moperone Chemical compound C1=CC(C)=CC=C1C1(O)CCN(CCCC(=O)C=2C=CC(F)=CC=2)CC1 AGAHNABIDCTLHW-UHFFFAOYSA-N 0.000 description 1
• 230000008450 motivation Effects 0.000 description 1
• 230000004118 muscle contraction Effects 0.000 description 1
• NFZIHKNNXDBZMI-UHFFFAOYSA-N n-[1-[(5-chlorothiophen-2-yl)methyl]-2,3-dihydroindol-5-yl]-2-phenoxyacetamide Chemical compound S1C(Cl)=CC=C1CN1C2=CC=C(NC(=O)COC=3C=CC=CC=3)C=C2CC1 NFZIHKNNXDBZMI-UHFFFAOYSA-N 0.000 description 1
• ILXWQQLVKRBUAO-UHFFFAOYSA-N n-[2-amino-4-[(3-fluoroanilino)methyl]phenyl]-2,2-dimethylpropanamide Chemical compound C1=C(N)C(NC(=O)C(C)(C)C)=CC=C1CNC1=CC=CC(F)=C1 ILXWQQLVKRBUAO-UHFFFAOYSA-N 0.000 description 1
• GOXFPLZEUOSYNS-UHFFFAOYSA-N n-[2-amino-4-[(5-chlorothiophen-2-yl)methylamino]phenyl]-2-(4-fluorophenyl)acetamide Chemical compound C=1C=C(NC(=O)CC=2C=CC(F)=CC=2)C(N)=CC=1NCC1=CC=C(Cl)S1 GOXFPLZEUOSYNS-UHFFFAOYSA-N 0.000 description 1
• OWIUPIRUAQMTTK-UHFFFAOYSA-M n-aminocarbamate Chemical compound NNC([O-])=O OWIUPIRUAQMTTK-UHFFFAOYSA-M 0.000 description 1
• 230000008693 nausea Effects 0.000 description 1
• KPSSIOMAKSHJJG-UHFFFAOYSA-N neopentyl alcohol Chemical compound CC(C)(C)CO KPSSIOMAKSHJJG-UHFFFAOYSA-N 0.000 description 1
• 208000004296 neuralgia Diseases 0.000 description 1
• 230000008587 neuronal excitability Effects 0.000 description 1
• 125000005187 nonenyl group Chemical group C(=CCCCCCCC)* 0.000 description 1
• 238000010606 normalization Methods 0.000 description 1
• 239000002777 nucleoside Substances 0.000 description 1
• 150000003833 nucleoside derivatives Chemical class 0.000 description 1
• 229950010634 ocaperidone Drugs 0.000 description 1
• 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
• 125000005069 octynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
• KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
• 229960005017 olanzapine Drugs 0.000 description 1
• 210000000287 oocyte Anatomy 0.000 description 1
• 229940127240 opiate Drugs 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 125000003544 oxime group Chemical group 0.000 description 1
• 229960001057 paliperidone Drugs 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 244000052769 pathogen Species 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• BNIXVQGCZULYKV-UHFFFAOYSA-N pentachloroethane Chemical compound ClC(Cl)C(Cl)(Cl)Cl BNIXVQGCZULYKV-UHFFFAOYSA-N 0.000 description 1
• 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
• YWAKXRMUMFPDSH-UHFFFAOYSA-N pentene Chemical compound CCCC=C YWAKXRMUMFPDSH-UHFFFAOYSA-N 0.000 description 1
• 125000005981 pentynyl group Chemical group 0.000 description 1
• 229960002195 perazine Drugs 0.000 description 1
• WEYVCQFUGFRXOM-UHFFFAOYSA-N perazine Chemical compound C1CN(C)CCN1CCCN1C2=CC=CC=C2SC2=CC=CC=C21 WEYVCQFUGFRXOM-UHFFFAOYSA-N 0.000 description 1
• LUALIOATIOESLM-UHFFFAOYSA-N periciazine Chemical compound C1CC(O)CCN1CCCN1C2=CC(C#N)=CC=C2SC2=CC=CC=C21 LUALIOATIOESLM-UHFFFAOYSA-N 0.000 description 1
• 229960000769 periciazine Drugs 0.000 description 1
• 229960000762 perphenazine Drugs 0.000 description 1
• IAZAUSSUAOBMAY-UHFFFAOYSA-N phenyl n-anilinocarbamate Chemical compound C=1C=CC=CC=1OC(=O)NNC1=CC=CC=C1 IAZAUSSUAOBMAY-UHFFFAOYSA-N 0.000 description 1
• XVNKRRXASPPECQ-UHFFFAOYSA-N phenyl n-phenylcarbamate Chemical compound C=1C=CC=CC=1OC(=O)NC1=CC=CC=C1 XVNKRRXASPPECQ-UHFFFAOYSA-N 0.000 description 1
• 229940067157 phenylhydrazine Drugs 0.000 description 1
• 230000035479 physiological effects, processes and functions Effects 0.000 description 1
• YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 description 1
• 229960003634 pimozide Drugs 0.000 description 1
• JOMHSQGEWSNUKU-UHFFFAOYSA-N pipotiazine Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCC(CCO)CC1 JOMHSQGEWSNUKU-UHFFFAOYSA-N 0.000 description 1
• 229960003252 pipotiazine Drugs 0.000 description 1
• 239000004036 potassium channel stimulating agent Substances 0.000 description 1
• 229910001414 potassium ion Inorganic materials 0.000 description 1
• YRVIKLBSVVNSHF-JTQLQIEISA-N pozanicline Chemical compound CC1=NC=CC=C1OC[C@H]1NCCC1 YRVIKLBSVVNSHF-JTQLQIEISA-N 0.000 description 1
• 238000004321 preservation Methods 0.000 description 1
• YGKUEOZJFIXDGI-UHFFFAOYSA-N pridopidine Chemical compound C1CN(CCC)CCC1C1=CC=CC(S(C)(=O)=O)=C1 YGKUEOZJFIXDGI-UHFFFAOYSA-N 0.000 description 1
• 230000008569 process Effects 0.000 description 1
• 229960003111 prochlorperazine Drugs 0.000 description 1
• WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 1
• 239000000047 product Substances 0.000 description 1
• 210000001176 projection neuron Anatomy 0.000 description 1
• 229960003598 promazine Drugs 0.000 description 1
• 125000006308 propyl amino group Chemical group 0.000 description 1
• NUIPDYRCSYMGEO-UHFFFAOYSA-N propyl n-[2-iodo-4-[[4-(trifluoromethyl)phenyl]methylamino]phenyl]carbamate Chemical compound C1=C(I)C(NC(=O)OCCC)=CC=C1NCC1=CC=C(C(F)(F)F)C=C1 NUIPDYRCSYMGEO-UHFFFAOYSA-N 0.000 description 1
• JZWNUSQHKDGSPL-UHFFFAOYSA-N propyl n-[4-[(4-propan-2-ylphenyl)methylamino]-2-(trifluoromethyl)phenyl]carbamate Chemical compound C1=C(C(F)(F)F)C(NC(=O)OCCC)=CC=C1NCC1=CC=C(C(C)C)C=C1 JZWNUSQHKDGSPL-UHFFFAOYSA-N 0.000 description 1
• NFJFMYAGECOXQG-UHFFFAOYSA-N propyl n-[4-[(5-chlorothiophen-2-yl)methylamino]-2,6-dimethylphenyl]carbamate Chemical compound C1=C(C)C(NC(=O)OCCC)=C(C)C=C1NCC1=CC=C(Cl)S1 NFJFMYAGECOXQG-UHFFFAOYSA-N 0.000 description 1
• 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
• JTTAUPUMOLRVRA-UHFFFAOYSA-N prothipendyl Chemical group C1=CN=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 JTTAUPUMOLRVRA-UHFFFAOYSA-N 0.000 description 1
• 229960000957 prothipendyl Drugs 0.000 description 1
• 230000000506 psychotropic effect Effects 0.000 description 1
• JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 1
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
• 150000003248 quinolines Chemical class 0.000 description 1
• 230000035484 reaction time Effects 0.000 description 1
• 229960003448 remoxipride Drugs 0.000 description 1
• 230000004043 responsiveness Effects 0.000 description 1
• 230000036390 resting membrane potential Effects 0.000 description 1
• 238000007363 ring formation reaction Methods 0.000 description 1
• 125000006413 ring segment Chemical group 0.000 description 1
• 102220024624 rs267607620 Human genes 0.000 description 1
• YRNIQASZWVFCJP-UHFFFAOYSA-N s-ethyl carbamothioate Chemical compound CCSC(N)=O YRNIQASZWVFCJP-UHFFFAOYSA-N 0.000 description 1
• IQWCBYSUUOFOMF-QTLFRQQHSA-N sabcomeline Chemical compound C1CC2[C@@H](C(/C#N)=N/OC)CN1CC2 IQWCBYSUUOFOMF-QTLFRQQHSA-N 0.000 description 1
• 229950000425 sabcomeline Drugs 0.000 description 1
• 208000026451 salivation Diseases 0.000 description 1
• 239000004576 sand Substances 0.000 description 1
• 208000022610 schizoaffective disease Diseases 0.000 description 1
• 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 230000028327 secretion Effects 0.000 description 1
• 235000019615 sensations Nutrition 0.000 description 1
• 230000000862 serotonergic effect Effects 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 230000007958 sleep Effects 0.000 description 1
• 229910001415 sodium ion Inorganic materials 0.000 description 1
• 230000002269 spontaneous effect Effects 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
• PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical compound [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
• 150000003456 sulfonamides Chemical class 0.000 description 1
• BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
• RWSOTUBLDIXVET-UHFFFAOYSA-O sulfonium Chemical compound [SH3+] RWSOTUBLDIXVET-UHFFFAOYSA-O 0.000 description 1
• 229960004724 sultopride Drugs 0.000 description 1
• 230000009182 swimming Effects 0.000 description 1
• 230000002195 synergetic effect Effects 0.000 description 1
• 229950011332 talnetant Drugs 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• 150000003536 tetrazoles Chemical class 0.000 description 1
• 150000003557 thiazoles Chemical class 0.000 description 1
• 229960004728 thiopropazate Drugs 0.000 description 1
• AIUHRQHVWSUTGJ-UHFFFAOYSA-N thiopropazate Chemical compound C1CN(CCOC(=O)C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 AIUHRQHVWSUTGJ-UHFFFAOYSA-N 0.000 description 1
• 229960003397 thioproperazine Drugs 0.000 description 1
• VZYCZNZBPPHOFY-UHFFFAOYSA-N thioproperazine Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(C)CC1 VZYCZNZBPPHOFY-UHFFFAOYSA-N 0.000 description 1
• 229960005344 tiapride Drugs 0.000 description 1
• 229960005013 tiotixene Drugs 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
• 235000013769 triethyl citrate Nutrition 0.000 description 1
• 229960002324 trifluoperazine Drugs 0.000 description 1
• ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 description 1
• 229960002341 trifluperidol Drugs 0.000 description 1
• GPMXUUPHFNMNDH-UHFFFAOYSA-N trifluperidol Chemical compound C1CC(O)(C=2C=C(C=CC=2)C(F)(F)F)CCN1CCCC(=O)C1=CC=C(F)C=C1 GPMXUUPHFNMNDH-UHFFFAOYSA-N 0.000 description 1
• 229960003904 triflupromazine Drugs 0.000 description 1
• XSCGXQMFQXDFCW-UHFFFAOYSA-N triflupromazine Chemical compound C1=C(C(F)(F)F)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 XSCGXQMFQXDFCW-UHFFFAOYSA-N 0.000 description 1
• 229910052721 tungsten Inorganic materials 0.000 description 1
• 235000013976 turmeric Nutrition 0.000 description 1
• 210000004496 type 1 vestibular hair cell Anatomy 0.000 description 1
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
• NPTIPEQJIDTVKR-STQMWFEESA-N vabicaserin Chemical compound C1CNCC2=CC=CC3=C2N1C[C@@H]1CCC[C@@H]13 NPTIPEQJIDTVKR-STQMWFEESA-N 0.000 description 1
• 229950009968 vabicaserin Drugs 0.000 description 1
• RYJXBGGBZJGVQF-UHFFFAOYSA-N veralipride Chemical compound COC1=CC(S(N)(=O)=O)=CC(C(=O)NCC2N(CCC2)CC=C)=C1OC RYJXBGGBZJGVQF-UHFFFAOYSA-N 0.000 description 1
• 229960001968 veralipride Drugs 0.000 description 1
• 230000001720 vestibular Effects 0.000 description 1
• 230000000007 visual effect Effects 0.000 description 1
• 229940088594 vitamin Drugs 0.000 description 1
• 229930003231 vitamin Natural products 0.000 description 1
• 239000011782 vitamin Substances 0.000 description 1
• 235000013343 vitamin Nutrition 0.000 description 1
• 150000003722 vitamin derivatives Chemical class 0.000 description 1
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
• 238000009941 weaving Methods 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1
• 230000004584 weight gain Effects 0.000 description 1
• 235000019786 weight gain Nutrition 0.000 description 1
• 229960000607 ziprasidone Drugs 0.000 description 1
• MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 1
• 229960004496 zotepine Drugs 0.000 description 1
• HDOZVRUNCMBHFH-UHFFFAOYSA-N zotepine Chemical compound CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12 HDOZVRUNCMBHFH-UHFFFAOYSA-N 0.000 description 1
• 229960004141 zuclopenthixol Drugs 0.000 description 1